ROR1-specific chimeric antigen receptor and its therapeutic application
By designing a ROR1-specific CAR-T cell containing specific antigen binding domain, hinge region and costimulatory signaling domain, the problem of poor efficacy and adverse reactions of existing ROR1-targeted CAR-T cell therapy is solved. , achieving efficient killing and safety improvement of ROR1-positive tumor cells.
Patent Information
- Application Number
- CN202080067842.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-09
- Filing Date
- 2020-09-24
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-09-24
AI Technical Summary
The existing ROR1-targeted CAR-T cell therapy is not satisfactory in killing ROR1-positive tumor cells, and has certain adverse reactions, and has a high immune response to the human body, making it difficult to achieve a minimized effect.
A ROR1-specific chimeric antigen receptor (CAR) was developed, which includes an extracellular domain, a hinge region, a transmembrane region and an intracellular signal domain. The antigen-binding domain specifically binds to ROR1 antigen, using CD8 and CD28 Signal peptides such as CD137 and costimulatory domains enhance intracellular signaling, improve the killing ability of ROR1-positive tumor cells, and design and connect peptides through specific amino acid sequences to optimize the expression and function of CAR.
It has achieved efficient identification and killing of ROR1-positive tumor cells, significantly reduced adverse reactions to humans, improved efficacy and safety, had significant anti-tumor activity and no obvious toxic side effects on mammals themselves.
Smart Images

Figure CN114929751B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine or biopharmaceutical technology, and in particular to a ROR1-specific chimeric antigen receptor and its therapeutic application. Background Art
[0002] In recent years, an emerging immunotherapy called adoptive cell transfer (ACT) has developed rapidly. This therapy uses immune cells to eliminate cancer. Some methods involve obtaining natural immune cells and directly expanding their numbers, while other methods involve genetically engineering immune cells to enhance their anti-cancer capabilities.
[0003] In the case of cancer, immune cells called killer T cells are particularly effective in cancer treatment because they can bind to markers (i.e., antigens) on the surface of cancer cells. Cellular immunotherapy uses this natural ability in different ways, including tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, natural killer (NK) cell therapy, etc. Although there are many types of ACT therapies, CAR-T cell therapy has made the most progress in clinical development so far.
[0004] More and more CAR-T cell therapies are being developed for clinical research, and although there are many differences between these therapies, they all have similar components. The CAR on the cell surface is composed of a fragment or domain of a synthetic antibody, which affects the ability of the receptor to recognize or bind to tumor cell antigens; the receptor relies on stimulation signals from inside the cell to complete its work, so each CAR-T cell has an intracellular signaling domain and a "co-stimulatory" domain that sends signals from the surface receptor to the cell. The use of different domains affects the overall function of the cell. With the advancement of CAR-T cell intracellular engineering technology, the proliferation ability and survival time of T cells in patients have gradually improved.
[0005] ROR1 is a member of the orphan receptor family, which is highly conserved among species and is involved in controlling multiple signaling pathways such as cell growth and epithelial-mesenchymal transition (Shabani M, Naseri J, Shokri F. Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. Expert OpinTher Targets. 2015 Jul; 19(7): 941-55). Wnt5a is one of the ligands of ROR1 (Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, et al., Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci US A. 2008; 105(8): 3047–52).
[0006] ROR1 is considered to be a survival factor in a variety of malignancies, including chronic lymphocytic leukemia (CLL), breast cancer, lung adenocarcinoma, ovarian cancer, pancreatic cancer and glioblastoma (Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, et al., The receptor tyrosinekinase ROR1—an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol. 2014; 29: 21–31).
[0007] The amino terminus of ROR1 is an extracellular immunoglobulin-like domain, a cysteine-rich domain, also known as a Frizzled domain, and a highly folded and cysteine-rich Kringle transmembrane domain. The intracellular portion of ROR1 contains a tyrosine kinase domain whose kinase activity is controversial, a serine / threonine-rich domain, a proline-rich domain, and another serine / threonine-rich domain at the carboxyl terminus, which may be involved in protein interactions (Shabani M., Naseri J, Shokri F. Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. Expert Opin Ther Targets. 2015 Jul; 19 (7): 941-55). WNT5A is the only known ligand of ROR1 and binds to ROR1 through the Frizzled domain. The Klinger domain is responsible for heterodimerization with ROR2, another ROR family protein in CLL cells, which leads to the activation of small GTPases of the Rho family, and the subsequent proliferation and migration of cancer cells.
[0008] ROR1 is highly expressed during embryonic development of the central nervous system, heart, skeletal muscle and lung system. Except for adipose tissue, a small number of early B cell subsets and upper gastrointestinal cells, normal tissues of adults do not express ROR1 (Balakrishnan et al., Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res. 2016. Epub 2016 / 11 / 18).
[0009] ROR1 plays an important role in tumorigenesis through PI3K / AKT / mTOR pathway and EGFR-mediated signal transduction.
[0010] An important method for targeting ROR1 to treat cancer is to adoptively transfer CAR-T cells targeting ROR1. CAR-T cells are engineered T cells that express CARs, which are composed of binding domains or single-chain antibodies specific to tumor antigens (such as ROR1). The prepared ROR1-specific CARs have shown effective recognition of ROR1-expressing tumor cells both in vitro and in vivo. The adoptive transfer of these ROR1-specific CAR-T cells has been shown to safely and effectively eliminate ROR1 in primates. +B cells, but the current CAR-T effect targeting ROR1 is still unsatisfactory.
[0011] Double negative T cells (DNT cells) are mature peripheral T lymphocytes that express the CD3-TCR complex but do not express CD4, CD8 or the NKT cell markers αGalCer-CD1d and Jα24-Vα14, accounting for 1-5% of human peripheral blood mononuclear cells (PBMC) (Zhang et al., 2000). This treatment method can reduce the mortality rate of systemic or local inoculation of lethal doses of A20 lymphoma cells (Young et al., 2001; Young et al., 2003) by more than 75%. In addition, a protocol for extracting and expanding DNT cells from AML patients during complete remission of chemotherapy has been published, and it has been confirmed that DNT cells derived from AML patients have significant inhibitory activity against autologous primary AML cells (Young et al., 2003). Unlike CD4 or CD8 T cells, the infusion of ex vivo activated allogeneic DNT cells does not cause graft-versus-host disease (GVHD). In addition, the injection of allogeneic DNT cells can also prevent CD8 T recipients from developing GVHD.
[0012] DNT cells have excellent anti-tumor properties and can also prevent GVHD, so DNT cells are very suitable for preparing allogeneic CAR-T cells.
[0013] Therefore, there is an urgent need in the art to develop an immune cell that effectively targets ROR1, which can effectively and specifically target and kill ROR1-positive tumor cells while minimizing adverse reactions to the human body. Summary of the invention
[0014] The purpose of the present invention is to provide an immune cell that effectively targets ROR1, effectively and specifically eliminates ROR1-positive tumor cells, and at the same time minimizes adverse reactions to the human body.
[0015] In the first part, the present invention provides a chimeric antigen receptor (CAR), comprising:
[0016] (1) an extracellular domain comprising at least one antigen-binding domain (or scFv) that specifically binds to ROR1;
[0017] (2) Hinge region;
[0018] (3) transmembrane region;
[0019] (4) Intracellular signaling domain;
[0020] The antigen binding domain comprises a heavy chain variable region having heavy chain complementary determining region 1 (HCDR1), HCDR2 and HCDR3, and a light chain variable region having light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3;
[0021] Wherein, the polypeptide sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are selected from:
[0022] a. SEQ ID Nos: 2, 3, 4, 6, 7, 8; or
[0023] b. SEQ ID Nos: 16, 17, 18, 20, 21, 22; or
[0024] c.SEQ ID Nos: 30, 31, 32, 34, 35, 36;
[0025] Alternatively, the polypeptide sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are selected from the group consisting of:
[0026] a. Amino acids 1-2 (DA), 14 of SEQ ID Nos: 9, 10, 11, 12, 13; or
[0027] b. amino acids 1-2 (DA), 28 of SEQ ID Nos: 23, 24, 25, 26, 27; or
[0028] c. Amino acids 1-2 (DA) and 42 of SEQ ID Nos: 37, 38, 39, 40, 41;
[0029] In a preferred embodiment, the antigen binding domain or scFv specifically binds to receptor tyrosine kinase-like orphan receptor 1 (ROR1), preferably human ROR1; and
[0030] Any of the above polypeptide sequences also includes a derivative sequence formed by optionally adding, deleting, modifying and / or replacing 1-5 (or 1, 2, 3) amino acids and being able to retain ROR1 binding affinity.
[0031] In certain embodiments, the ROR1 antigen binding domain is a single chain variable fragment (scFv).
[0032] In preferred embodiments, the antigen binding domain comprises:
[0033] a. a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 1 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 5; or
[0034] b. a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 15 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 19; or
[0035] c. a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 29 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 33.
[0036] In a preferred embodiment, the scFv further comprises a connecting peptide between the heavy chain variable region and the light chain variable region.
[0037] In a preferred embodiment, the scFv is represented by Formula A or Formula B:
[0038] V H -V L (A);
[0039] V L -V H (B);
[0040] Among them, "V H ” is the variable region of antibody heavy chain, “V L ” is the variable region of antibody light chain, and “-” is a connecting peptide or peptide bond.
[0041] In a preferred embodiment, V H and V L The connecting peptide between them is (GGGGS) n , where n is 1, 2, 3, or 4.
[0042] In a preferred embodiment, V H and V L The connecting peptide therebetween is (GGGGS)3 (SEQ ID No: 47).
[0043] In a preferred embodiment, the structure of CAR is as shown in Formula I:
[0044] L-scFv-H-TM-C-CD3ζ (I)
[0045] in,
[0046] “L” represents no or signal peptide sequence;
[0047] "scFv" represents the ROR1 antigen binding domain as defined above;
[0048] “H” stands for None or Hinge;
[0049] “TM” stands for transmembrane domain;
[0050] “C” represents the costimulatory signaling domain;
[0051] “CD3ζ” represents the intracellular signaling sequence derived from CD3ζ;
[0052] Each "-" represents an independent connecting peptide or peptide bond.
[0053] In a preferred embodiment, "L" is a signal peptide selected from proteins such as CD8, CD28, GM-CSF, CD4, CD137, and combinations thereof.
[0054] In a preferred embodiment, "L" is a signal peptide derived from CD8.
[0055] In a preferred embodiment, "L" has the amino acid sequence shown in SEQ ID NO:43.
[0056] In a preferred embodiment, "H" is a hinge region selected from proteins such as CD8, CD28, CD137, and combinations thereof.
[0057] In a preferred embodiment, "H" is the hinge region derived from CD8.
[0058] In a preferred embodiment, "H" has the amino acid sequence shown at positions 1-44 in SEQ ID NO:44.
[0059] In a preferred embodiment, "TM" is a transmembrane region selected from proteins such as CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, and combinations thereof.
[0060] In a preferred embodiment, "TM" is a transmembrane region derived from CD8 or CD28.
[0061] In a preferred embodiment, the transmembrane region derived from CD8 has the amino acid sequence shown at positions 45 to 69 in SEQ ID NO:44.
[0062] In a preferred embodiment, "C" is a co-stimulatory signaling domain selected from OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137), PD1, Dap10, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), NKG2D, GITR, TLR2, and combinations thereof.
[0063] In a preferred embodiment, "C" is a co-stimulatory signaling domain derived from CD28 and / or 4-1BB.
[0064] In a preferred embodiment, the 4-1BB-derived co-stimulatory signal molecule has an amino acid sequence as shown in SEQ ID NO:45.
[0065] In a preferred embodiment, CD3ζ has the amino acid sequence shown in SEQ ID NO:46.
[0066] In a preferred embodiment, the ROR1-specific CAR has at least 85%, preferably at least 90%, more preferably at least 95%, and most preferably at least 99% sequence identity to the amino acid sequence of SEQ ID NO:48, 49 or 50.
[0067] In a preferred embodiment, V H Chain and V L The chains are respectively related to SEQ ID NO: 1, 15, 29 (V H ) and SEQ ID NO: 5, 19, 33 (V L ) have at least 80%, preferably at least 90%, more preferably at least 95%, most preferably at least 99% sequence identity.
[0068] In the second part, the present invention provides a bispecific CAR that targets a first target and a second target, wherein the first target is ROR1.
[0069] In a preferred embodiment, the second target is selected from CD19, CD20 or a combination thereof.
[0070] In preferred embodiments, the scFv is human, chimeric or fully humanized.
[0071] In the third part, the present invention provides a nucleic acid molecule encoding the first part CAR or the second part bispecific CAR of the present invention.
[0072] In preferred embodiments, the nucleic acid molecule is DNA or RNA.
[0073] In the fourth part, the present invention provides a vector containing the nucleic acid molecule of the third part of the present invention.
[0074] In a preferred embodiment, the vector is selected from the group consisting of a plasmid, a viral vector (such as a lentiviral vector, an adenoviral vector or a retroviral vector), and a combination thereof.
[0075] In a preferred embodiment, the vector is a lentiviral vector.
[0076] In the fifth part, the present invention provides an engineered host cell, which comprises the vector of the fourth part of the present invention, or integrates the nucleic acid molecule of the third part of the present invention into the chromosome or genome, or expresses the CAR of the first part of the present invention or expresses the bispecific CAR of the second part.
[0077] In the sixth part, the present invention provides an engineered immune cell, which comprises the vector of the fourth part of the present invention, or integrates the nucleic acid molecule of the third part of the present invention into the chromosome or genome, or expresses the CAR of the first part of the present invention or expresses the bispecific CAR of the second part.
[0078] In preferred embodiments, the modified immune cells are autologous or allogeneic cells.
[0079] In a preferred embodiment, the engineered immune cell is selected from:
[0080] (1) Chimeric antigen receptor T cells (CAR-T cells); or
[0081] (2) Chimeric antigen receptor NK cells (CAR-NK cells).
[0082] In a preferred embodiment, the modified immune cell is a cytotoxic T lymphocyte.
[0083] In a preferred embodiment, the modified immune cell is a double negative T cell (DNT cell).
[0084] In a preferred embodiment, the modified immune cells express a ROR1-specific CAR on the cell surface.
[0085] In the seventh part, the present invention provides a pharmaceutical composition or preparation, which contains the CAR of the first or second part of the present invention, the vector of the fourth part, or the engineered immune cell of the sixth part, and a pharmaceutically acceptable carrier, diluent or excipient.
[0086] In a preferred embodiment, the pharmaceutical composition is a liquid formulation.
[0087] In a preferred embodiment, the pharmaceutical composition is an injection.
[0088] In a preferred embodiment, the concentration of engineered immune cells in the pharmaceutical composition is 1×10 3 -1×10 8 cells / mL, preferably 1×10 4 -1×10 7 cells / mL.
[0089] The eighth section provides the CAR of the first or second section, the vector of the fourth section, or the engineered immune cell of the sixth section of the present invention, for use in preparing a drug or preparation for preventing and / or treating cancer.
[0090] In the ninth part, the present invention provides a method for preparing an engineered immune cell, wherein the engineered immune cell expresses the CAR of the first part or the second part of the present invention. The method comprises the following steps: transducing the nucleic acid molecule of the third part of the present invention or the vector of the fourth part into the immune cell, thereby obtaining the engineered immune cell.
[0091] In preferred embodiments, the immune cell is a T cell or a NK cell.
[0092] In a preferred embodiment, the immune cell is a DN T cell.
[0093] In the tenth part, the present invention provides a kit for preparing the engineered immune cells of the sixth part of the present invention, which comprises a container with the nucleic acid molecule of the third part or the vector of the fourth part of the present invention.
[0094] The eleventh section provides the use of the vector of the fourth section or the engineered immune cell of the sixth section of the present invention for preventing and / or treating cancer or tumors.
[0095] In the twelfth part, the present invention provides a method for treating a disease, comprising administering the vector of the fourth part, the engineered immune cell of the sixth part, or the preparation or composition of the seventh part to a subject in need thereof.
[0096] In a preferred embodiment, the disease treated is cancer.
[0097] In preferred embodiments, the subject is a human.
[0098] In a preferred embodiment, the cancer is a premalignant or malignant tumor characterized by ROR1 expressing cells.
[0099] In a preferred embodiment, the cancer comprises a non-solid tumor.
[0100] In a preferred embodiment, the cancer is a hematological malignancy.
[0101] In particularly preferred embodiments, the hematological malignancy is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, mantle cell lymphoma (MCL), or acute lymphocytic leukemia (ALL).
[0102] In a preferred embodiment, the cancer comprises a solid tumor.
[0103] In particularly preferred embodiments, the solid tumor is breast cancer, prostate cancer, liver cancer, lung cancer, pancreatic cancer, colon cancer or kidney cancer.
[0104] Part 13, the present invention provides a method for engineering modified immune cells, comprising:
[0105] (1) Provide immune cells;
[0106] (2) Express at least one ROR1-specific CAR.
[0107] In another embodiment, the engineering method comprises:
[0108] (1) Provide immune cells;
[0109] (2) introducing at least one polynucleotide encoding a ROR1-specific CAR into the modified immune cell;
[0110] (3) expressing at least one polynucleotide on the surface of the modified immune cell.
[0111] In another embodiment, the engineering method comprises:
[0112] (1) Provide immune cells;
[0113] (2) introducing at least one CAR expression vector into the modified immune cell;
[0114] (3) The modified immune cells express at least one polynucleotide on their surface.
[0115] The modified immune cells of the present invention are particularly suitable for disease treatment. In one embodiment, the modified immune cells are used to produce and treat cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0116] Figure 1A Lentiviral vectors are shown; Figure 1B The structure of the anti-ROR1 chimeric antigen receptor (CAR) is shown.
[0117] Figure 2 The results of phenotypic testing of human peripheral blood PBMCs are shown.
[0118] Figure 3 Shown are the results of anti-ROR1-C3-CAR lentiviral infection of T cells and phenotypic testing.
[0119] Figure 4 Results of anti-ROR1-G3-CAR lentivirus-infected T cells are shown, and NT refers to non-lentivirus-infected T cells.
[0120] Figure 5 The results of in vitro proliferation of anti-ROR1-G3-CAR-T cells are shown.
[0121] Figure 6 Results of proliferating anti-ROR1-G3-CAR-T cell subsets and phenotypes are shown.
[0122] Figure 7Results for ROR1 expression in tumor cell lines are shown.
[0123] Figure 8 The cytokine release results of anti-ROR1-C3-CAR-T cells co-cultured with ROR1-positive target cells are shown.
[0124] Fig. 9 Shown are the cytokine release results of anti-ROR1-G3-CAR-T cells co-cultured with ROR1-overexpressing SK-OV-3 cells and ROR1-overexpressing U87MG cells.
[0125] Fig.10 Showing the results of lysis and killing of ROR1-positive target cells by anti-ROR1-C3-CAR-T cells.
[0126] Fig.11 Showing the in vitro cell killing results of anti-ROR1-C3-CAR-T cells on ROR1-positive target cells.
[0127] Fig.12 The results of cell killing by anti-ROR1-G3-CAR-T cells against co-cultured SK-OV-3 and U87MG cells overexpressing ROR1 are shown.
[0128] Fig.13 The in vivo antitumor activity results of anti-ROR1-C3-CAR-T cells in the MDA-MB-231 xenograft mouse tumor model are shown.
[0129] Fig.14 The results show the in vivo antitumor activity of anti-ROR1-G3-CAR-T cells in the Jeko1 xenograft mouse tumor model.
[0130] Fig.15 The results show the in vivo antitumor activity of anti-ROR1-G3-CAR-T cells in Jeko1 xenograft mice.
[0131] Fig.16 The results show the in vivo antitumor activity of anti-ROR1-G3-CAR-T cells in the SK-OV-3-ROR1 xenograft mouse tumor model.
[0132] Fig.17 The results show the in vivo antitumor activity of anti-ROR1-G3-CAR-T cells in the U87MG-ROR1 xenograft mouse tumor model.
[0133] Fig.18 The anti-ROR1-G3-CAR-DNT research strategy is shown.
[0134] Fig.19The results of human peripheral blood DNT phenotype detection are shown.
[0135] Fig. 20 Shown are the results of anti-ROR1-G3-CAR lentivirus-infected DNT cells.
[0136] Fig.21 Subpopulation and phenotypic results of anti-ROR1-G3-CAR-DNT cells after expansion are shown.
[0137] Fig. 22 The results showing the in vitro proliferation of anti-ROR1-G3-CAR-DNT cells.
[0138] Fig.23 Shown are the cytokine release results of co-culture of anti-ROR1-G3-CAR-DNT cells with ROR1-overexpressing U87MG cells.
[0139] Fig.24 The results of cell killing by co-culture of ROR1-overexpressing U87MG cells with anti-ROR1-G3-CAR-DNT cells were detected by FACS method. DETAILED DESCRIPTION
[0140] Through in-depth research and extensive screening, the inventors unexpectedly obtained a group of fully human ROR1 antibodies with a completely new amino acid sequence. The ROR1 antibodies have extremely high affinity to human ROR1 protein and extremely low or even no immunogenicity to humans. Therefore, they are particularly suitable for constructing ROR-targeted chimeric antigen receptors for the treatment of ROR1-related diseases such as tumors. The present invention was completed on this basis.
[0141] Specifically, the inventors constructed CAR-T cells using scFvs of different ROR1 antibodies and compared their effects. Unexpectedly, some of the scFvs had better effects, including high killing ability against ROR1 overexpressing cells and ROR1 positive tumor target cells. The ROR1-specific chimeric antigen receptor (CAR) of the present invention comprises: a signal peptide, an anti-ROR1 antibody V H and V L The extracellular ROR1 antigen binding domain, hinge, transmembrane domain, co-stimulatory domain and intracellular signaling domain ( Figure 1B ), this type of ROR1-specific CAR has an unexpectedly excellent anti-tumor effect.
[0142] definition:
[0143] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the invention belongs. In other cases, some terms used herein will clarify their meanings in the specification.
[0144] It should be noted that as used in the specification and claims of the present invention, the singular forms "a", "an" and "the" include plural references unless the context clearly dictates otherwise.
[0145] Unless otherwise indicated, any numerical value, such as the concentration or concentration range described herein, is understood to be modified by the term "about" in all cases. Therefore, numerical values generally include ±10% of the value described. For example, a concentration of 1 mg / mL includes 0.9 mg / mL to 1.1 mg / mL. Similarly, a concentration range of 1% to 10% (w / v) includes 0.9% (w / v) to 11% (w / v). The numerical ranges herein explicitly include all possible subranges, all individual values within the range, and integers and fractions within the range.
[0146] Unless otherwise indicated, the term "at least" in a series of elements should be understood to include every element in the series. Those skilled in the art will recognize or be able to determine using only routine experimentation the specific embodiments of the invention described herein or many equivalents. The present invention encompasses such equivalents.
[0147] The terms "include", "comprising", "having" or any other similar words used herein will be understood to include the stated integers or combinations of integers, but not to exclude any other integers or combinations of integers, and are meant to be non-exclusive or open-ended. For example, compositions, mixtures, preparations, methods, articles, or devices, these words need not be limited to the elements on the words, but may include other elements not expressly listed or inherent in these words. In addition, unless the contrary meaning is clearly indicated, "or" refers to an inclusive "or" rather than an exclusive "or". For example, condition A or B satisfies any of the following conditions: A is true (or exists) and B is false (or does not exist), A is false (or does not exist) and B is true (or exists), and A and B are both true (or exist).
[0148] The term "and / or" used herein to combine multiple listed elements should be understood to cover both individual elements and combined elements. For example, when two elements are connected by "and / or", the first applicable option refers to the first element without the second element; the second applicable option refers to the second element without the first element; the third applicable option refers to both the first and second elements. Any of these options or situations where more than one option is applicable should be considered within the above meaning and meet the criteria for using the term "and / or" herein.
[0149] The term "consisting of" or other similar words used in this specification and claims means that any integer or combination of integers is included, but additional elements or combinations of integers cannot be added to the specified method, structure or combination.
[0150] As used in this specification and claims, "consisting essentially of..." or other similar words, it means including any listed integers or combinations of integers, and optionally including any integers or combinations of integers that do not materially change the basic or novel properties of the particular method, structure or composition.
[0151] The "subject" herein refers to any animal, preferably a mammal, and most preferably a human. As shown herein, the term "mammal" refers to any mammal, examples of which include but are not limited to cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., but the best choice is human.
[0152] The terms “right,” “left,” “lower,” and “upper” as used herein designate directions in the drawings to which reference is made.
[0153] When referring to the dimensions or characteristics of the elements of the invention, the terms "approximately", "substantially", "substantially" and similar terms used herein are consistent with the general understanding of those skilled in the art. These words do not strictly limit the range or parameters of the described dimensions / characteristics, but do not exclude minor variations that are functionally the same or similar. Such references to numerical parameters include variables that do not change the least significant digits, at least in accordance with mathematical and industrial principles recognized in the art (such as rounding, measurement or other systematic errors, manufacturing tolerances, etc.).
[0154] The terms "identical" or "percent identity" in the context of two or more nucleic acid or polypeptide sequences (e.g., anti-ROR1 antibodies and polynucleotides encoding them, ROR1 polypeptides and ROR1 polynucleotides encoding them) refer to two or more sequences or subsequences that are the same or have a particular percentage of amino acid residues or nucleotides that are the same when compared and aligned for maximum correspondence using a sequence alignment algorithm or by visual inspection.
[0155] Sequence alignment usually uses one sequence as a reference sequence to compare with the test sequence. When using a sequence alignment algorithm, the test sequence and the reference sequence are input into a computer, subsequence coordinates are set if necessary, and algorithm program parameters are set, and then the sequence alignment algorithm calculates the sequence identity percentage of the test sequence relative to the reference sequence based on the set program parameters.
[0156] Optimal sequence alignment methods for comparison include the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), the search similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally, Current Protocols in Molecular Biology, FM Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1995 Supplement) (Ausubel)).
[0157] Suitable examples for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402, respectively. Software for performing BLAST analyses is publicly available from the National Center for Biotechnology Information (NCBI). The algorithm first identifies high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that match or satisfy a certain positive threshold score T when aligned with a word of the same length in the database sequence. T is called the neibourhood words score threshold (Altschul et al., supra). These initial neighborhood words hits serve as seeds for initiating searches to find longer HSPs containing them. The hits are then extended in both directions along each sequence until the cumulative alignment score increases.
[0158] For nucleotide sequences, the cumulative score is calculated using the parameters M (reward score for a pair of matching residues; >0) and N (penalty score for mismatched residues; <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the fragment hit in each direction will stop when: the cumulative alignment score drops by the amount X from its maximum achieved value; the cumulative score becomes zero or lower due to the accumulation of one or more negative scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment, and the BLASTN program (for nucleotide sequences) uses a fragment length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a control of both chains by default. For amino acid sequences, the BLASTP program uses a fragment length (W) of 3, an expectation (E) of 10, and a BLOSEIM62 scoring matrix by default (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. ETSA 89:10915 (1989)).
[0159] In addition to calculating the percentage of sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat T. Acad. Sci. ETSA 90:5873-5787 (1993)). A similarity calculation provided by the BLAST algorithm is the smallest total probability (P(N)), which indicates the probability of a match occurring by chance between two nucleotide or amino acid sequences. For example, if the smallest total probability is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001 in a comparison of a test nucleic acid to a reference sequence, the nucleic acid is considered similar to the reference sequence.
[0160] As described below, a further indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross-reactive with the polypeptide encoded by the second nucleic acid, whereby the polypeptide is generally substantially identical to the second polypeptide, e.g., the two peptides differ only in conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions.
[0161] The term "polynucleotide" as used herein is defined as a chain of nucleotides, and nucleic acids are polymers of nucleotides, so nucleic acids and polynucleotides used herein are used interchangeably. It is well known to those skilled in the art that nucleic acids are polynucleotides, which can be hydrolyzed into monomeric "nucleotides", which can be hydrolyzed into nucleosides. The polynucleotides referred to herein include, but are not limited to, all nucleic acid sequences obtained by any means available in the art, including, but not limited to, recombinant means, i.e., cloning nucleic acid sequences from a recombinant library or a cell genome, using common cloning techniques and PCR. TM etc., as well as by synthetic means.
[0162] The terms "peptide", "polypeptide" and "protein" used herein are used interchangeably and refer to compounds composed of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that constitute a protein or peptide sequence. The above terms used herein include long chains and short chains, and short chains are also commonly referred to as peptides, oligopeptides and oligomers in the art; while for longer chains, they are generally referred to as proteins in the art, which include many types, for example, "polypeptides" include biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, etc.
[0163] As used herein, the term "antigen-binding fragment" refers to a polypeptide fragment comprising at least one CDR of an immunoglobulin heavy chain and / or light chain that binds to an antigen of interest. In a particularly preferred embodiment herein, the antigen is receptor tyrosine kinase-like orphan receptor 1 (ROR1). The antigen-binding fragment of the antibody described herein may comprise a V from an antibody that binds to ROR1. H and / or V L One, two, three, four, five or all six CDRs on the sequence. The antigen-binding fragments of the ROR1-specific antibodies described herein are capable of binding to ROR1. In other embodiments, the binding of the antigen-binding fragment prevents or inhibits the binding of the ROR1 ligand to the ROR1 receptor, interrupting the biological response originally caused by the binding of the ligand to the receptor. In certain embodiments, the antigen-binding fragment specifically binds to and / or inhibits or modulates the biological activity of ROR1.
[0164] The term "antigen" refers to a molecule or a portion of a protein molecule that can be bound by a selective binding agent (eg, an antibody) and can also be administered to an animal to produce antibodies that can bind to the antigen epitope. An antigen may have one or more epitopes.
[0165] The term "epitope" includes any determinant, preferably a polypeptide determinant, that is capable of specific binding to an immunoglobulin or T-cell receptor. An epitope is a region of an antigen that is bound by an antibody. In certain embodiments, an epitope determinant includes chemically active surface groups of a molecule, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and in certain embodiments may have specific three-dimensional structural characteristics and / or specific charge characteristics. In certain embodiments, an antibody is said to specifically bind to an antigen when it preferentially recognizes a target antigen in a complex mixture of proteins and / or macromolecules. According to certain embodiments, an antibody is said to specifically bind to an antigen when the equilibrium dissociation constant for antibody-antigen binding is less than or equal to 10 -6 M, or less than or equal to 10 -7 M, or less than or equal to 10 -8When M, it can be said that the antibody specifically binds to the antigen. In some embodiments, the equilibrium dissociation constant can be less than or equal to 10 -9 M, or less than or equal to 10 -10 M.
[0166] The term "vector" refers to any molecule (e.g., nucleic acid, plasmid or virus) used to transfer coding information to a host cell. The term "expression vector" refers to a vector suitable for transforming a host cell and carrying a nucleic acid sequence that directs and / or controls the expression of an inserted heterologous nucleic acid sequence, including but not limited to processes such as transcription, translation and RNA splicing if introns are present.
[0167] The term "autologous" refers to any material from the same individual that is reintroduced into that individual.
[0168] The term "allogeneic" refers to a transplant that originates from a different animal of the same species.
[0169] The term "xenograft" refers to a transplant that originates from a different animal of a different species.
[0170] The term "lentivirus" as used herein refers to a genus of the Retroviridae family. Lentiviruses are unique among retroviruses in that they are able to infect non-dividing cells; they can transfer large amounts of genetic information into the DNA of host cells and are one of the most effective methods of gene delivery vectors. HIV, SIV, and FIV are all examples of lentiviruses. Vectors derived from lentiviruses provide a means of achieving significant levels of gene transfer in vivo.
[0171] The term "cancer" as used herein refers to a disease characterized by the rapid and uncontrolled growth of abnormal cells. Cancer cells can spread locally or to other parts of the body through the blood and lymphatic system. Examples of various cancers include, but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, kidney cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, etc.
[0172] As used herein, the term "anti-tumor effect" can be manifested as a reduction in tumor volume, a reduction in the number of tumor cells, a reduction in the number of metastases, an increase in life expectancy, or an improvement in various physiological symptoms associated with cancer. "Anti-tumor effect" can also be manifested by the ability of the peptides, polynucleotides, cells and antibodies of the present invention to prevent the first occurrence of tumors.
[0173] As used herein, the term "treating" a disease refers to reducing the frequency or severity of at least one sign or symptom of the disease or condition experienced by a subject.
[0174] Antibodies and scFv
[0175] The term "antibody" as used herein is a broad usage, including immunoglobulins or antibody molecules, antibody molecules including human antibodies, humanized antibodies, composite antibodies and chimeric antibodies and monoclonal or polyclonal antibody fragments. Generally, antibodies are proteins or peptide chains that exhibit binding specificity to specific antigens, and their structures are well known. According to a specific embodiment, the antibody of the present invention includes a heavy chain and / or light chain constant region from a human antibody, in addition to the heavy chain and light chain constant domains, the antibody also includes an antigen binding region, consisting of a light chain variable region and a heavy chain variable region, each heavy chain variable region includes three domains (i.e., complementary determining regions 1-3; CDR1, CDR2 and CDR3), the light chain variable region domain is also referred to as LCDR1, LCDR2 and LCDR3, and the heavy chain variable region domain is also referred to as HCDR1, HCDR2 and HCDR3.
[0176] As used herein, the term "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to ROR1 is substantially free of antibodies that do not bind to ROR1), and the isolated antibody is substantially free of other cellular material and / or chemicals.
[0177] The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous antibody population, meaning that the individual antibodies constituting the population are identical except for possible natural mutations present in small amounts. The monoclonal antibodies of the present invention can be prepared by hybridoma method, phage display technology, single lymphocyte gene cloning technology or recombinant DNA method, for example, monoclonal antibodies can be produced by hybridomas, which include B cells obtained from transgenic non-human animals such as transgenic mice or rats, which have a genome comprising human heavy chain transgenes and light chain transgenes.
[0178] The term "antigen binding fragment" as used herein refers to an antibody fragment, such as a bispecific antibody, Fab, Fab', F(ab')2, an Fv fragment, a disulfide-stabilized Fv fragment (dsFv), (dsFv)2, a bispecific dsFv (dsFv-dsFv1), a disulfide-stabilized bispecific antibody, a single-chain antibody molecule (scFv), a single-domain antibody (sdab), a scFv dimer (a bivalent bispecific antibody), a multispecific antibody formed by a portion of an antibody comprising one or more CDRs, a camelized single-domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not contain a complete antibody structure. An antigen binding fragment is capable of binding to the same antigen to which a parent antibody or parent antibody fragment binds. According to specific embodiments, the antigen binding fragment comprises a light chain variable region, a light chain constant region, and an Fd segment of a heavy chain. According to other specific embodiments, the antigen binding fragment comprises Fab and F(ab').
[0179] The term "single-chain antibody" as used herein refers to a conventional single-chain antibody in the art, which comprises a heavy chain variable region and a light chain variable region connected by a short peptide of about 15 to 20 amino acids. The term "single-domain antibody" as used herein refers to a conventional single-domain antibody in the art, which comprises a heavy chain variable region and a heavy chain constant region, or only comprises a heavy chain variable region.
[0180] The term "human antibody" as used herein refers to an antibody produced by humans or an antibody having an amino acid sequence corresponding to an antibody produced by humans prepared using any technique known in the art. The definition of a human antibody includes complete or full-length antibodies, fragments thereof and / or antibodies comprising at least one human heavy chain and / or light chain polypeptide.
[0181] The term "humanized antibody" as used herein refers to a non-human antibody that has been modified to increase sequences homologous to human antibodies, thereby retaining the antigen-binding properties of the antibody while reducing its antigenicity in the human body.
[0182] The term "chimeric antibody" as used herein refers to an antibody whose immunoglobulin molecule amino acid sequence is derived from two or more species. The variable regions of the light and heavy chains usually correspond to the variable regions of antibodies with the desired specificity, affinity and avidity derived from one mammal (e.g., mouse, rat, rabbit, etc.), while the constant regions correspond to antibody sequences derived from another mammal (e.g., human) to avoid inducing an immune response in that species.
[0183] As used herein, an "antibody that specifically binds to ROR1" refers to an antibody that binds to ROR1, preferably human ROR1, with a specific binding affinity of 1×10 -7 M or less, preferably 1×10-8 M or less, more preferably 5×10 -9 M or smaller, 1×10 -9 M or smaller, 5×10 -10 M or smaller, 1×10 -10 M or smaller K D The term "K D ” refers to the dissociation constant, which is derived from K d and K a The ratio (K d / K a ) and expressed as molar concentration (M). The present application can use the methods in the art to determine the antibody K D For example, the K D can be determined by using surface plasmon resonance, for example by using a biosensor system ( systems), or by using biolayer interferometry, such as the Octet RED96 system.
[0184] Antibody K D The smaller the value, the higher the affinity of the antibody binding to the target antigen.
[0185] The term "specific binding" for antibodies used herein refers to antibodies that recognize a specific antigen but do not substantially recognize or bind to other molecules in the sample. For example, an antibody that specifically binds to an antigen from one species may also bind to antigens from one or more species, but this cross-species reactivity itself does not change the specific classification of the antibody. In another embodiment, an antibody that specifically binds to an antigen may also bind to an antigen in a different allele form, but this cross-reaction itself does not change the specific classification of the antibody. In some cases, the term "specific binding" or "specific binding" may be used to refer to the interaction of an antibody, protein or peptide with a second chemical substance, indicating that the interaction depends on the presence of a specific structure (e.g., an antigenic determinant or epitope) on the chemical substance; for example, an antibody recognizes and binds to a specific protein structure, rather than the general structure of the protein. If the antibody is specific for epitope "A", then in a reaction containing a marker "A" and an antibody, the presence of a molecule containing epitope A (or free, unlabeled A) will reduce the amount of marker A bound to the antibody.
[0186] In certain embodiments, antibodies and antigen-binding fragments thereof as described herein include heavy chain and light chain CDR sets, which are inserted between heavy chain and light chain framework regions (FR) sets, respectively, and the set provides support for CDR and defines the spatial relationship of CDR relative to each other. As used herein, the term "CDR set" refers to three hypervariable regions of heavy chain or light chain variable region, starting from the N-terminus of heavy chain or light chain, and these regions are respectively expressed as "CDR1", "CDR2" and "CDR3", and therefore, the antigen binding site includes six CDRs, including CDR sets from each of the heavy chain and light chain variable regions. A polypeptide comprising a single CDR (e.g., CDR1, CDR2 or CDR3) is referred to herein as a "molecular recognition unit". Crystallographic analysis of many antigen-antibody complexes shows that the amino acid residues of CDR form extensive contacts with the bound antigen, and the most extensive contact with the antigen is the heavy chain CDR3. Therefore, the molecular recognition unit is primarily responsible for the specificity of the antigen binding site.
[0187] As used herein, the term "FR set" refers to the four amino acid sequences flanking the CDRs that make up the variable region of a heavy or light chain. Some FR residues may contact the bound antigen, however, FRs are primarily responsible for folding the variable region into the antigen binding site, especially the FR residues directly adjacent to the CDRs. Among FRs, certain amino acid residues and certain structural features are extremely highly conserved, and in this regard, all variable region sequences contain an internal disulfide loop of approximately 90 amino acid residues. When the variable region folds into the binding site, the CDR appears as a protruding circular motif that forms the antigen binding surface. It is generally believed that regardless of the exact CDR amino acid sequence, the conserved structural regions of the FRs affect the folding of the CDR loops into certain "canonical" structures. In addition, it is known that certain FR residues are involved in non-covalent interdomain contacts that stabilize the interaction between the heavy and light chains of antibodies.
[0188] The structure and location of immunoglobulin variable regions can be found in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 4 th Edition, US Department of Health and Human Services, 1987, and its updates, now available on the Internet (immuno.bme.nwu.edu).
[0189] As used herein, "antibody heavy chain" refers to the larger of the two types of polypeptide chains present in all antibody molecules in their native structure. The heavy chains of any vertebrate species can be classified into one of the following five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM, which are also designated as α, δ, ε, γ, and μ, respectively. The IgG and IgA classes are further divided into subclasses based on differences in sequence and function, and humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.
[0190] As used herein, "antibody light chain" refers to the smaller of the two types of polypeptide chains present in all antibody molecules in their native structure, kappa and lambda light chains being the two major antibody light chain isotypes.
[0191] The term "synthetic antibody" as used herein refers to an antibody produced using recombinant DNA technology, such as an antibody expressed by a bacteriophage as described herein. The term should also be interpreted as an antibody generated by synthesizing a DNA molecule encoding an antibody, and the DNA molecule expresses an antibody protein, or specifies an amino acid sequence of an antibody, wherein the DNA or amino acid sequence is obtained using a technique for synthesizing DNA or amino acid sequences that is customary and well known in the art.
[0192] In a preferred embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof (or scFv) comprises a heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, the polypeptide sequence of which is selected from the following group:
[0193] a. SEQ ID Nos: 2, 3, 4, 6, 7, 8; or
[0194] b. SEQ ID Nos: 16, 17, 18, 20, 21, 22; or
[0195] c.SEQ ID Nos: 30, 31, 32, 34, 35, 36;
[0196] The antibody or antigen-binding fragment thereof specifically binds to ROR1, preferably human ROR1.
[0197] In a preferred embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof (or scFv) comprises a heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, the polypeptide sequence of which is selected from the following group:
[0198] a. Amino acids 1-2 (DA), 14 of SEQ ID Nos: 9, 10, 11, 12, 13; or
[0199] b. amino acids 1-2 (DA), 28 of SEQ ID Nos: 23, 24, 25, 26, 27; or
[0200] c. Amino acids 1-2 (DA) and 42 of SEQ ID Nos: 37, 38, 39, 40, 41;
[0201] The antibody or antigen-binding fragment thereof specifically binds to ROR1, preferably human ROR1.
[0202] In a preferred embodiment, the present invention provides an isolated monoclonal antibody or antigen-binding fragment thereof (such as scFv) comprising a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or more, for example 95%, 96%, 97%, 98% or 99% identical to one of SEQ ID NOs: 1, 15 or 29; or a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or more, for example 95%, 96%, 97%, 98% or 99% identical to one of SEQ ID NOs: 5, 19 or 33.
[0203] In the present invention, the antibodies or antigen-binding fragments thereof (such as scFv) of the present invention also include conservative mutants, i.e., polypeptides in which up to 10, preferably up to 8, more preferably up to 5, and most preferably up to 3 amino acids are replaced by amino acids having the same or similar properties compared to the amino acid sequence of the antibody of the present invention. These conservative mutant polypeptides are preferably produced according to the amino acid substitutions in Table A.
[0204] Table A
[0205]
[0206]
[0207] Chimeric antigen receptors, coding sequences and vectors
[0208] The present invention also provides a chimeric antigen receptor targeting ROR1, and corresponding coding sequences or polynucleotides and vectors.
[0209] The term "chimeric antigen receptor (CAR)" as used herein refers to a molecule having a binding domain that is capable of targeting an element expressed on a target cell, such as a chimeric protein that exhibits specific anti-target cell immune activity based on the specificity of an antibody against a target antigen (such as a tumor antigen) and the activation intracellular domain of a T cell receptor.
[0210] The chimeric antigen receptor (CAR) of the present invention includes an extracellular domain, a transmembrane domain and an intracellular domain, the extracellular domain includes a target-specific binding element (also called an antigen binding domain), and the intracellular domain includes a co-stimulatory signal region and a zeta (ζ) chain portion.
[0211] Typically, CARs consist of an extracellular single-chain antibody fused to the intracellular signaling domain of the zeta chain of the T-cell antigen receptor complex and have the ability to redirect antigen recognition according to antibody specificity when expressed in T cells.
[0212] Preferably, the CAR of the present invention comprises: a signal peptide, an anti-ROR1 antibody V H and V L The extracellular antigen-binding domain, hinge, transmembrane domain, co-stimulatory domain and intracellular signaling domain.
[0213] As used herein, the term "extracellular antigen binding domain" refers to an oligopeptide or polypeptide that is capable of binding to a ligand. Preferably, the domain will be able to interact with molecules on the cell surface, for example, an extracellular antigen binding domain can be selected to recognize a ligand that acts as a cell surface marker on a target cell associated with a particular disease state.
[0214] For example, the extracellular antigen binding domain can be selected to recognize a ligand that acts as a cell surface marker on a target cell associated with a specific disease state. The extracellular antigen binding domain of the anti-ROR1 CAR can be any domain that binds to an extracellular antigen, including but not limited to a monoclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, and a functional fragment thereof. In some embodiments, the extracellular antigen binding domain comprises a single-chain antibody fragment (scFv) comprising a target antigen-specific anti-ROR1 antibody light chain (V L ) and heavy chain (V H ) variable fragment. Preferably, the single-chain antibody or scFV is an amino acid chain sequence encoded by a nucleotide sequence.
[0215] Preferably, V L and V H Select from antibody clones C3, G3 or G6 shown in Table 2.
[0216] About transmembrane domain, CAR can be designed to include transmembrane domain fused with the extracellular domain of CAR.In one embodiment, a transmembrane domain naturally associated with one of the domains of CAR is used.In some cases, the transmembrane domain can be screened or modified by amino acid replacement to avoid binding of the domain to the transmembrane domain of the same or different surface membrane protein, thereby minimizing the interaction with other parts of the receptor complex.
[0217] The transmembrane domain can be derived from a natural or synthetic source, and the domain of a natural source can be from any membrane-bound protein or transmembrane protein. The transmembrane region used in the present invention can be derived from (i.e., at least including its transmembrane region) T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or the transmembrane domain can be synthesized, and under this source it will mainly include hydrophobic residues, such as leucine and valine. Preferably, there are triplets of phenylalanine, tryptophan and valine at both ends of the synthetic transmembrane domain. Optionally, a short oligopeptide or polypeptide having a length between 2 and 10 amino acids can form a connection between the transmembrane domain of CAR and the intracellular signaling domain, and a glycine-serine doublet is a particularly suitable connecting peptide.
[0218] Preferably, the transmembrane domain in the CAR of the present invention is a CD8α transmembrane domain. In some cases, the transmembrane domain in the CAR of the present invention comprises a CD8α hinge domain. In one embodiment, the CD8α transmembrane domain and the CD8α hinge domain comprise the amino acid sequence of SEQ ID NO: 2.
[0219] The intracellular domain or other intracellular signaling domain of the CAR of the present invention is responsible for activating at least one normal effector function of the immune cell expressing CAR. The term "effector function" refers to the special function of the cell, for example, the effector function of T cells can be cytolytic activity or auxiliary activity, including the secretion of cytokines. The term "intracellular signaling domain" refers to a protein portion that transduces effector function signals and instructs cells to perform specific functions. Although the entire intracellular signaling domain can usually be used, it is not necessary to use the entire chain in many cases. As far as the truncated portion of the intracellular signaling domain is used, as long as it transduces the effector function signal, it can be used to replace the complete chain. Therefore, the term "intracellular signaling domain" includes any truncated portion in the intracellular signaling domain that can transduce the effector function signal.
[0220] Preferred examples of the intracellular signaling domain of the CAR used in the present invention include intracellular sequences of T cell receptors (TCRs) and co-receptors, which act synergistically to initiate signal transduction after antigen receptor binding, and any derivatives or variants of the above sequences and synthetic sequences have the same function.
[0221] It is well known that the signal generated by the TCR alone is not sufficient to fully activate T cells, and secondary or co-stimulatory signals are also required. Therefore, it can be said that T cell activation is mediated by two different types of intracellular signaling sequences: sequences that initiate antigen-dependent primary activation through the TCR (primary intracellular signaling sequences), and sequences that act in an antigen-independent manner to provide secondary or co-stimulatory signals (secondary intracellular signaling sequences).
[0222] The primary intracellular signaling sequence regulates the primary activation of the TCR complex in a stimulatory or inhibitory manner. The primary intracellular signaling sequence acting in a stimulatory manner may contain signaling motifs that are immunoreceptor tyrosine-based activation motifs or ITAMs.
[0223] The ITAM containing the primary intracellular signal sequence used in the present invention includes sequences derived from TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b and CD66d. Particularly preferably, the intracellular signal molecule in the CAR of the present invention comprises an intracellular signal sequence derived from CD3ζ.
[0224] In a preferred embodiment, the intracellular domain of CAR can be designed to include the CD3ζ signaling domain itself or any other useful intracellular domain combination in the context of the CAR of the present invention, such as the intracellular domain of CAR can include a CD3ζ chain portion and a costimulatory signal region, and the costimulatory signal region refers to the portion of the intracellular domain of the costimulatory molecule in CAR. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands required for lymphocytes to effectively respond to antigens, including CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands specifically bound to CD83, etc. Therefore, although the present invention is mainly illustrated by 4-1BB as a costimulatory signal portion, other costimulatory molecules are also within the scope of the present invention.
[0225] More specifically, the ROR1-specific CAR of the present invention comprises a CD8α signal peptide, an extracellular ROR1 binding domain, a CD8α hinge, a CD8α transmembrane domain, an intracellular CD3ζ signaling domain, and a co-stimulatory domain from 4-1BB.
[0226] In one embodiment, the intracellular domain in the CAR of the present invention is designed to contain the costimulatory domain of 4-1BB and the signaling domain of CD3ζ.
[0227] CAR immune cells
[0228] The present invention also provides modified immune cells (e.g., T cells) engineered to express CAR, wherein the CAR immune cells (e.g., CAR-T cells or CAR-NK cells) exhibit anti-tumor properties.
[0229] The term "immune cell" or "immune effector cell" used herein refers to a cell involved in an immune response, such as a cell involved in promoting an immune effector response, and includes T cells, B cells, natural killer (NK) cells, mast cells, and myeloid phagocytes. According to a specific embodiment, the engineered immune cell is a T cell, and is referred to as a CAR-T cell, which is engineered to express the CAR of the present invention.
[0230] The term "modified immune cell" used herein refers to a cell comprising an exogenous polynucleotide sequence encoding a CAR and expressing at least one CAR as described above. According to a specific embodiment, the engineered immune cell has been genetically modified to express the CAR construct of the present invention.
[0231] The immune cell may be a dendritic cell, a killer dendritic cell, a mast cell, a NK cell, a B cell or a T cell, wherein the T cell is selected from inflammatory T lymphocytes, cytotoxic T lymphocytes, regulatory T lymphocytes or helper T lymphocytes. + T lymphocytes and CD8 + Combination of T lymphocytes.
[0232] Immune cells and their precursor cells can be separated by methods known in the art, including methods using existing commercial products (see Rowland Jones et al., Lymphocytes: A Practical Approach, Oxford University Press, NY 1999), and the sources of immune cells or their precursors include but are not limited to peripheral blood, umbilical cord blood, bone marrow or other hematopoietic cell sources. A variety of techniques can be used to separate or enrich the desired immune cells, for example, negative screening methods can be used to remove non-target immune cells, in addition, positive screening methods can be used to separate or enrich the desired immune cells or their precursors, or a combination of positive and negative screening methods can be used. If a specific type of cell is to be separated, such as a specific T cell, its cell surface marker or a combination of markers (e.g., CD3, CD4, CD8, CD34) can be used to separate the cells.
[0233] In the treatment method of the present invention, the immune cells or their precursor cells administered to the subject can be autologous or non-autologous, and the autologous cells are isolated from the subject's body of the engineered immune cells to which the recombinant expression of CAR is to be administered. The cells can be obtained by leukocyte removal, which selectively removes leukocytes from the extracted blood, recombines, and then transfuses them to the donor. Alternatively, allogeneic cells from non-autologous donors of non-subjects can be used, and in the case of non-autologous donors, the cells are typed and human leukocyte antigens (HLA) are matched to confirm the compatibility level. For autologous and non-autologous cells, the cells can be selected to be cryopreserved until ready for use.
[0234] In the present invention, cells can preferably be obtained from a number of non-limiting sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue at the site of infection, ascites, pleural effusion, spleen tissue and tumors, and can also be from T cell lines available and known to those skilled in the art, or from healthy donors, patients diagnosed with cancer.
[0235] According to a specific embodiment, the method for manufacturing engineered immune cells includes transfecting or transducing immune effector cells separated from an individual so that the immune effector cells express one or more CARs of the embodiments of the present invention. WO2014 / 130635 discloses a method for preparing immune cells for immunotherapy, and WO2014 / 039523 and WO2014 / 184741 disclose various steps for preparing engineered immune cells, and the aforementioned documents are incorporated into the present application document by reference in their entirety.
[0236] In a specific embodiment, immune effector cells (such as T cells) are genetically modified (for example, transduced with a viral vector comprising a nucleic acid encoding CAR) with the CAR of the present invention, and then activated and proliferated in vitro. In various embodiments, the method described in US6352694, U57144575 and US7067318 can be used to activate and amplify T cells to express CAR before or after genetic modification, and these documents are incorporated into the present application document by reference in full. T cells can be proliferated in vitro or in vivo, and generally speaking, the T cells of the present invention can be proliferated by stimulating the reagents of CD3 / TCR complex-related signals and stimulating the ligands of T cell surface co-stimulatory molecules. As a non-limiting example of stimulating T cell proliferation, it can be contacted with anti-CD3 antibodies or their antigen-binding fragments, or fixed on the cell surface anti-CD3 antibodies, or contacted with protein kinase C activators (such as bryostatin) in combination with calcium ion carriers, or by activating CAR itself. In order to costimulate the auxiliary molecules on the surface of T cells, a ligand bound to an auxiliary molecule is used, for example, T cells can be contacted with anti-CD3 antibodies and anti-CD28 antibodies, and T cell proliferation is stimulated under appropriate conditions. Appropriate conditions for T cell culture include: appropriate culture medium (e.g., Minimal Essential Media, RPMI Media 1640 or X-vivo 5 (Lonza)) containing factors required for proliferation and activation, including serum (e.g., fetal bovine or human serum), cytokines (e.g., IL-2, IL-7, IL-15 and / or IL-21, insulin, IFN-g, GM-CSF, TGFβ3), and / or any other additives known to those skilled in the art for cell growth. In other embodiments, methods such as those disclosed in US6040177, US5827642 and WO2012129514 may also be used, the method using cultured cells and suitable antibodies and cytokines to activate and stimulate T cell proliferation, the aforementioned documents are incorporated into the present application document by reference in their entirety.
[0237] When the CAR of the present invention is expressed in T cells, the CAR can recognize antigens based on antigen binding specificity. When the CAR-T cells of the present invention bind to cognate antigens, they inhibit tumor cell growth, promote tumor cell death or are otherwise affected, thereby reducing or eliminating the patient's tumor burden.
[0238] Pharmaceutical composition
[0239] The present invention also provides a pharmaceutical composition comprising the isolated polynucleotides, isolated polypeptides, host cells and / or engineered immune cells of the present invention, and a pharmaceutically acceptable carrier. The term "pharmaceutical composition" as used herein refers to a product comprising the isolated polynucleotides, isolated polypeptides, host cells and / or engineered immune cells of the present invention and a pharmaceutically acceptable carrier, and the polynucleotides, polypeptides, host cells and / or engineered immune cells of the present invention and compositions thereof can also be used to manufacture the drugs for the therapeutic applications mentioned above.
[0240] The term "carrier" as used herein refers to any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid-containing vesicle, microsphere, liposome encapsulation or other materials known in the art for pharmaceutical preparations. It should be understood that the characteristics of the carrier, excipient or diluent will depend on the route of administration for a specific application. The term "pharmaceutically acceptable carrier" as used herein refers to a non-toxic material that does not interfere with the effectiveness or biological activity of the compositions of the present invention. According to specific embodiments, any pharmaceutically acceptable carrier suitable for polynucleotides, polypeptides, host cells and / or engineered immune cell pharmaceutical compositions can be suitable for the present invention.
[0241] The preparation of active pharmaceutical ingredients and pharmaceutically acceptable carriers is common knowledge in the art, such as Remington: The Science and Practice of Pharmacy (2005, 21st edition and any updated edition). Non-limiting examples of additional ingredients include: buffers, diluents, solvents, tension regulators, preservatives, stabilizers and chelating agents. The pharmaceutical composition of the present invention can be formulated using one or more pharmaceutically acceptable carriers.
[0242] Preferably, the composition of the present invention is a liquid preparation, such as an aqueous preparation or an injection.
[0243] The pharmaceutical composition of the present invention is formulated to be compatible with its intended route of administration, which can be intravenous, peritoneal, intramuscular, subcutaneous, intradermal, transmucosal or intratumoral administration.
[0244] Pharmaceutical compositions suitable for injection include sterile aqueous solutions or dispersions, and sterile powders for the extemporaneous preparation of sterile injection solutions or dispersions, for example, sterilization can be accomplished by filtration through a sterile filtration membrane. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In many cases, isotonic agents such as sugars, polyols such as mannitol, sorbitol and sodium chloride are preferably included in the composition.
[0245] Therapeutic applications
[0246] CARs, expression vectors and modified immune cells can be used to treat patients with premalignant or malignant tumors characterized by ROR1-expressing cells, particularly overexpression of ROR1, which are common in hematological malignancies, such as leukemia.
[0247] The leukemia may be acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, acute lymphocytic leukemia, chronic lymphocytic leukemia, and myelodysplastic syndrome.
[0248] According to a preferred embodiment, the modified immune cells of the present invention are provided for use in treating chronic lymphocytic leukemia (CLL) or acute lymphocytic leukemia (ALL).
[0249] The types of cancers treated by the CAR of the present invention include, but are not limited to, non-solid tumors (e.g., hematological malignancies), and adult tumors / cancers and pediatric tumors / cancers are also included.
[0250] In addition, solid tumors such as breast, colon, liver, lung, kidney, pancreas, prostate, kidney and ovary can also be treated by the CAR of the present invention.
[0251] The main advantages of the present invention include:
[0252] (a) The antibodies of the present invention have excellent biological activity and specificity, have good binding affinity to cell surface ROR1, and can be used as scFV elements of ROR1-targeting antibodies and ROR1-targeting CARs;
[0253] (b) The fully human antibodies and scFVs of the present invention not only have activities comparable to those of immune antibodies, but also have lower immunogenicity;
[0254] (c) The antibodies of the present invention and the CAR targeting ROR1 both have significant anti-tumor activity and have no obvious toxic side effects on mammals themselves;
[0255] (d) The antibodies and CAR targeting ROR1 of the present invention not only have significant therapeutic effects in tumor models, but are also applicable to other diseases associated with high expression of ROR1.
[0256] The following examples will further illustrate the present invention. It should be understood that the present examples are only used to describe the present invention and are not intended to limit the scope of the present invention. The experimental methods of the examples, if no specific conditions are specified, are usually carried out under conventional conditions, such as the conditions described in Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise stated, the percentages and other numerical values mentioned in the examples refer to weight percentages and weights. The cell lines are conventional products commercially available or purchased from ATCC, and all plasmids are commercially available products.
[0257] Cell lines:
[0258] All cell lines were obtained from the American Type Culture Collection (ATCC). Jeko-1 and MDA-MB-231, NCL-H358, NCL-H1975, HT-29, SK-OV-3, U87MG, and SK-OV-3 cells overexpressing ROR1 were cultured in RPMI1640 containing 10% FBS; 293T, PAN02, PANC-1, and A549 cells were cultured in DMEM1640 containing 10% FBS; the culture conditions were 37°C and 5% CO2.
[0259] Example 1: Screening of anti-ROR1 specific binders from a fully human phage antibody library
[0260] Human anti-ROR1 antibodies were synthesized using a phage display system, which were generated by using a proprietary enhanced human-derived phage library (ProMab Biotechnologies, Inc.).
[0261] Anti-ROR1 antibody clones C3, G3 and G6 are three high-affinity antibodies with V H and V L The amino acid sequences are shown in Table 1.
[0262] Table 1. Amino acid sequences of anti-ROR1 antibody clones C3, G3 and G6.
[0263]
[0264]
[0265]
[0266]
[0267] Table 2. Antibody VH 、V L and CDR sequence ID
[0268]
[0269]
[0270] The affinities of the above three antibody clones for human ROR1 are shown below.
[0271]
[0272] Epitope mapping of the interaction between anti-ROR1 antibodies and ROR1 showed that C3 and G3 bind to the Kringle domain of ROR1, and G6 binds to the immunoglobulin-like domain of ROR1.
[0273] Example 2: Construction of anti-ROR1 chimeric antigen receptor (anti-ROR1-CAR) expression vector
[0274] The CAR of the present invention with a fully human anti-ROR1 scFv is designed to include an EF1α promoter operatively linked to the anti-ROR1 scFv, hinge and transmembrane domains from CD8α and 4-1BB co-stimulatory domains, and then the intracellular signaling domain of the CD3ζ chain. The anti-ROR1-CAR also includes a CD8α signal peptide sequence for expression on the surface of immune effector cells. The amino acid sequences of the CAR components other than the scFv are shown in Table 3. The construction of the anti-ROR1-CAR is shown in Table 3. Figure 1B shown.
[0275] Table 3. Sequences of CAR components other than scFv
[0276]
[0277]
[0278] The amino acid sequences of the scFv encoded by the three anti-ROR1 CAR constructs are as follows:
[0279]
[0280] The anti-ROR1-CAR lentiviral vector was constructed by standard laboratory protocols. Briefly, the linearized plasmid of GV401 was obtained by digestion with BamHI restriction endonuclease (NEB, Cat: R0136L). The anti-ROR1-scFv sequence was synthesized by GENEIWIZ Inc., and the anti-ROR1-CAR gene fragment was obtained by PCR amplification using amplification primers.
[0281] Primers designed with homologous recombination sequences were inserted into the 5' end, and the anti-ROR1-CAR lentiviral vector plasmid was constructed by overlapping PCR amplification. The anti-ROR1-CAR lentiviral vector structure is as follows Figure 1A The aforementioned recombinant plasmid was used to transform E. coli, and then clones were picked for PCR sequencing identification. The clones with the correct sequence were cultured and extracted for packaging lentivirus.
[0282] Example 3: Preparation of lentivirus carrying anti-ROR1-CAR vector
[0283] The anti-ROR1-CAR lentivirus was manufactured using standard laboratory methods. Briefly, 2 × 10 6 HEK293T cells were seeded in a 10 cm culture dish and then transfected with lipofectamine3000 reagent (Invitrogen, Cat: L3000015) and a transfection vector; on the second day, the anti-ROR1-CAR-GV401 vector, the pHelper1.0 vector containing gag, pol, and rev genes, and the pHelper1.0 vector containing the VSVG pseudotype envelope gene were packaged; on the third day, the culture medium was replaced; on the fifth day, the supernatant was collected and centrifuged at 4000g for 10 minutes to remove the cellular components, filtered with a 0.45 micron filter, and then the supernatant containing the lentivirus was centrifuged at 4°C and 25000rpm for 2 hours, and then the supernatant was discarded, the virus preservation solution was added, and stored at -80°C for later use.
[0284] Example 4: Isolation of PBMCs from peripheral blood and phenotypic testing
[0285] Peripheral blood mononuclear cells (PBMCs) were isolated from fresh peripheral blood of healthy volunteers. First, 10-20 mL of fresh peripheral blood was collected from healthy volunteers using a vacuum blood collector and anticoagulant, and then the fresh blood was transferred to a 50 mL centrifuge tube and centrifuged at 2000 rpm for 10 minutes at room temperature; after discarding the upper plasma, the cells were diluted 1:1 with normal saline and gently pipetted up and down 3-5 times; then, 15 mL of Ficoll-Hypaque lymphocyte separation solution (GE, Cat: 17-1440-02) was added to the 50 mL centrifuge tube, and then the diluted peripheral blood was slowly added, and the sample was centrifuged at 2000 rpm for 30 minutes at room temperature; finally, the supernatant was carefully transferred to a new 50 mL centrifuge tube, and the lymphocytes were washed 3 times with normal saline. Detection of CD3 using flow cytometry + (BD, Cat: 552852), CD4 + (BD, Cat: 555347) and CD8 + (BD, Cat: 555369) The proportion of cell subpopulations, the results are as follows Figure 2shown.
[0286] Example 5: PBMC infection with anti-ROR1-CAR lentivirus
[0287] PBMCs were collected at 1.5×10 6 / mL resuspended and inoculated in 2mL per 6-well plate, and 1mg / mL CD3 (Miltenyi, Cat: 170-076-116) and 0.5mg / mL CD28 (Miltenyi, Cat: 170-076-116) soluble antibodies and 15μg / mL Retronectin (Takara, Cat: T100A) were added for cell activation; the next day, anti-ROR1-CAR lentivirus with an MOI of 3 was added to each well. Two days later, the cells were recovered and inoculated with 1.5×10 6 / mL density and were used for FACS and co-culture experiments four days later.
[0288] Example 6: Evaluation of infection efficiency and phenotype of anti-ROR1-CAR-T cells by FACS
[0289] Method 1
[0290] A lentiviral vector separated by self-cleaving peptide 2A and expressing anti-ROR1-CAR and green fluorescent protein was constructed to confirm the expression efficiency of anti-ROR1-CAR. The expression efficiency of anti-ROR1-CAR was confirmed by detecting green fluorescent protein by flow cytometry (FACS). The infection efficiency detection and phenotypic analysis were as follows: First, 1×10 6 The cells were infected with the aforementioned lentivirus, rinsed twice with washing buffer, and then 15 μL APC anti-human CD8 antibody (BD, Catalog No.: 555369), 15 μL PE anti-human CD4 antibody (BD, Catalog No.: 555347), and 15 μL PerCY5.5 anti-human CD3 antibody (BD, Catalog No.: 552852) were added, and incubated at 4°C in the dark for 30 minutes; second, the sample was centrifuged at 1000 rpm at room temperature for 5 minutes, and then the supernatant was removed; third, FACS buffer was added to rinse twice, and then centrifuged at 1000 rpm at room temperature for 5 minutes; finally, the cells were suspended with 150 μL FACS buffer, and fluorescence was detected by FACS.
[0291] Method 2
[0292] A lentiviral vector separated by self-cleaving peptide 2A and expressing anti-ROR1-CAR and green fluorescent protein was constructed to confirm the expression efficiency of anti-ROR1-CAR. The expression efficiency of anti-ROR1-CAR was confirmed by detecting green fluorescent protein by flow cytometry (FACS). The infection efficiency detection and phenotypic analysis were as follows: First, 1×106 The cells were infected with the aforementioned lentivirus, washed twice with washing buffer, and then 15 μL APC anti-human CD8 antibody (BD, Catalog No.: 555369), 15 μL PE anti-human CD4 antibody (BD, Catalog No.: 555347), 15 μL PerCY5.5 anti-human CD3 antibody (BD, Catalog No.: 552852), 5 μL Braliant Violiant 510TM anti-human CD45RO antibody (Biolegend, Catalog No.: 304246), 5 μL Brilliant Violiant 421TM anti-human CD197 antibody (CCR7) (Biolegend, Catalog No.: 353208) were added, and incubated at 4°C in the dark for 30 minutes; second, the sample was centrifuged at 1000 rpm at room temperature for 5 minutes, and then the supernatant was removed; third, FACS buffer was added to rinse twice, and then centrifuged at 1000 rpm at room temperature for 5 minutes; finally, the cells were washed with 150 μL Resuspend in FACS buffer and detect fluorescence by FACS.
[0293] Various modifications to the embodiments are obvious to those skilled in the art. The steps defined in Method 1 and Method 2 are universal and can be used for the analysis of other anti-ROR1-CAR-T cells.
[0294] 6.1 Analysis of anti-ROR1-C3-CAR-T cells
[0295] Anti-ROR1-C3-CAR-T cells were analyzed using method 1, and the analysis results are shown in Figure 3 The infection efficiency of T cells was about 40%, of which 35% of the T cells were CD4 T cells and 65% of the T cells were CD8 T cells.
[0296] 6.2 Analysis of anti-ROR1-G3-CAR-T cells
[0297] Anti-ROR1-G3-CAR-T cells were analyzed using method 2, and the analysis results are shown in Figure 4 and Figure 6 The infection efficiency of T cells was about 54%, of which 30% of T cells were CD4 T cells and 70% of T cells were CD8 T cells; 46.5% of anti-ROR1-G3-CAR-T cells were central memory T cells, 28% of anti-ROR1-G3-CAR-T cells were effector T cells, and 20% of anti-ROR1-G3-CAR-T cells were naive T cells ( T cells).
[0298] Example 7: Evaluation and comparison of proliferation of non-transduced T cells and anti-ROR1-CAR-T cells
[0299] To evaluate the proliferation of anti-ROR1-CAR-T cells in vitro, 0.5×10 6 / mL anti-ROR1-CAR-T cells, CD19-CAR-T cells and non-transduced T cells were cultured in TexMACS (Miltenyi, catalog number: 170-076-309) + 10% FBS + 200 IU / mL IL-2 (Miltenyi, catalog number: 130-097-748) + 100 μg / mL penicillin and 100 μg / mL streptomycin, respectively. The complete culture medium was replaced every 2 days and the number of T cells was counted.
[0300] Analysis of anti-ROR1-G3-CAR-T cells, the results are as follows Figure 5 As shown, the expansion number of anti-ROR1-G3-CAR-T cells remained similar to that of untransduced T cells.
[0301] Example 8: Screening of ROR1-positive and ROR1-negative cell lines
[0302] Eight human cell lines (see Table 4) were analyzed by FACS to identify ROR1 cell lines with different cell surface expression levels. The cells were suspended in PBS containing 0.5% BSA and anti-ROR1 antibody (BD, Cat. No. 564474), then incubated at 4°C for 30 minutes, and then the cells were washed twice with washing buffer and ROR1 expression was detected.
[0303] The results are as follows Figure 7 As shown, MDA-MB-231, PANC-1, HT-29, A549, NCL-H358, NCL-H1975, and Jeko-1 cells abundantly expressed ROR1, while PAN02 cells did not express ROR1.
[0304] The above cell lines were used to test the activity of anti-ROR1-CAR.
[0305] Table 4. ROR1 expression in different cell lines
[0306] Cell lines Cell Type ROR1 expression MDA-MB-231 Breast cancer Positive PANC1 Pancreatic epithelial carcinoma Positive PAN02 Pancreatic epithelial carcinoma Negative NCL-H358 Non-small cell lung cancer Positive NCL-H1975 Non-small cell lung cancer Positive A549 Lung adenocarcinoma Positive HT-29 Colorectal adenocarcinoma Positive Jeko-1 Mantle cell lymphoma Positive
[0307] Example 9: Cytokine release assay
[0308] Method 1
[0309] The human TH1 / TH2 cytokine CBA kit (BD, Cat. No. 550749) was used to evaluate the killing biological activity of anti-ROR1-CAR-T cells against ROR1-positive and ROR1-negative tumor cells.
[0310] Anti-ROR1-CAR-T cells or PBMCs were co-administered with MDA-MB-231 (ROR1+ )、PANC-1(ROR1 + )、NCL-H358(ROR1 + )、NCL-H1975(ROR1 + )、A549(ROR1 + )、HT-29(ROR1 + )、Jeko-1(ROR1 + ) or PAN02(ROR1 - ) cell lines were co-cultured for 24 hours. The specific steps of the experiment were as follows: First, the target cells (ROR1 + ) and non-target cells (ROR1 - ) and washed twice with washing buffer, and the cells were suspended in RPMI1640 containing 2% FBS and diluted to 1×10 6 The anti-ROR1-CAR-T cells and PBMC cells (effector cells) were then recovered and diluted to 1×10 6 100 μL of target cells (ROR1 + ) or non-target cells (ROR1 - ) were mixed with 100 μL of anti-ROR1-CAR-T cells or PBMCs in a 96-well plate at a ratio of 1:1 and co-cultured at 37°C for 20-24 hours; the second step was to recover 100 μL of culture medium, centrifuge at 1000 rpm for 5 minutes, and take the supernatant for cytokine release detection; the third step was to take out the cytokine capture beads and mix them thoroughly, add 50 μL of mixed beads and 50 μL of PE detection reagent to each supernatant sample (50 μL), mix them thoroughly and incubate them at room temperature in the dark for 3 hours, then add 1 mL of washing buffer to each sample, centrifuge at 200 g for 5 minutes, remove the supernatant and add 300 μL of washing buffer to each sample to suspend the beads; finally, analyze the samples by flow cytometry.
[0311] Method 2
[0312] The killing biological activity of anti-ROR1-CAR-T cells against ROR1-overexpressing SK-OV-3 and U87MG cells was evaluated by using a human TH1 / TH2 cytokine CBA kit (BD, Cat. No. 550749).
[0313] Anti-ROR1-CAR-T cells or PBMCs were co-cultured with ROR1-overexpressing SK-OV-3 and U87MG cell lines for 24 h. The experimental details were as follows: First, target cells (ROR1-overexpressing SK-OV-3 and U87MG cells) and non-target cells (SK-OV-3 and U87MG) were recovered and washed twice with washing buffer, and the cells were suspended in RPMI1640 containing 2% FBS and diluted to 1×10 6 The anti-ROR1-CAR-T cells and PBMC cells (effector cells) were then recovered and diluted to 1×10 6 At a concentration of 1 cell / mL, 100 μL of target cells (ROR1-overexpressing SK-OV-3 and U87MG cells) or non-target cells (SK-OV-3 and U87MG) were mixed with 100 μL of anti-ROR1-CAR-T cells or PBMCs in a 96-well plate at a ratio of 1:1 and co-cultured at 37°C for 20-24 hours; second, 100 μL of culture medium was recovered and centrifuged at 1000 rpm for 5 minutes, and the supernatant was used for cytokine release detection; third, the cytokine capture beads were taken out and mixed thoroughly, 50 μL of the mixed beads and 50 μL of PE detection reagent were added to each supernatant sample (50 μL), mixed thoroughly and incubated at room temperature in the dark for 3 hours, then 1 mL of washing buffer was added to each sample, and centrifuged at 200 g for 5 minutes. After removing the supernatant, 300 μL of washing buffer was added to each sample to suspend the beads; finally, the samples were analyzed by flow cytometry.
[0314] Various modifications to the embodiments are obvious to those skilled in the art. The steps defined in Method 1 and Method 2 are universal and can be used for the analysis of other anti-ROR1-CAR-T cells.
[0315] 9.1 Analysis of anti-ROR1-C3-CAR-T cells
[0316] Method 1 was used to evaluate the killing biological activity of anti-ROR1-C3-CAR-T cells against ROR1-positive and ROR1-negative tumor cells.
[0317] The results are as follows Figure 8 As shown, anti-ROR1-C3-CAR-T cells will release IL-2, TNFα, and IFNγ only in the presence of ROR1-positive cells, that is, anti-ROR1-C3-CAR-T cells will produce cytokines only when co-cultured with ROR1-positive target cells, but not when co-cultured with ROR1-negative cells, proving that CAR-T cells have the ability to specifically kill ROR1-positive tumor cell lines and have no killing effect on normal cells.
[0318] 9.2 Analysis of anti-ROR1-G3-CAR-T cells
[0319] Method 2 was used to evaluate the killing biological activity of anti-ROR1-G3-CAR-T cells against ROR1-overexpressing SK-OV-3 and U87MG cells.
[0320] The results are as follows Fig. 9 As shown in the figure, anti-ROR1-G3-CAR-T cells will release IL-2, TNFα, and IFNγ only in the presence of target cells (ROR1-overexpressing SK-OV-3 and U87MG cells), that is, anti-ROR1-G3-CAR-T cells will produce cytokines only when co-cultured with ROR1-positive target cells (ROR1-overexpressing SK-OV-3 and U87MG cells), but not when co-cultured with ROR1-negative cells (SK-OV-3 and U87MG cells), proving that CAR-T cells have the ability to specifically kill ROR1-positive tumor cell lines and have no killing effect on normal cells.
[0321] Example 10: Cell lysis ability test
[0322] A co-culture assay was used to evaluate cell lysis caused by anti-ROR1-CAR-T cells. Anti-ROR1-CAR-T cells or PBMCs were co-cultured with MDA-MB-231 (ROR1 + )、PANC-1(ROR1 + )、NCL-H358(ROR1 + )、NCL-H1975(ROR1 + )、A549(ROR1 + )、HT-29(ROR1 + ) or PAN02(ROR1 - ) cells were co-cultured for 24 hours. The specific steps of the cell lysis assay are as follows: First, the target cells (ROR1 + ) and non-target cells (ROR1 - ) and washed twice with washing buffer, and the cells were suspended in RPMI1640 containing 2% FBS and diluted to 1×10 6 The anti-ROR1-CAR-T cells and PBMC cells (effector cells) were then recovered and diluted to 1×10 6 The concentration of cells / mL was set; effector cells and target cells or non-target cells were seeded in a 12-well plate at a ratio of 1:1 and co-cultured at 37°C for 24 hours; finally, cell survival rate was evaluated and photographed.
[0323] Analysis of anti-ROR1-CAR-T cells showed that anti-ROR1-C3-CAR-T cells led to the+ )、PANC-1(ROR1 + )、NCL-H358(ROR1 + )、NCL-H1975(ROR1 + )、A549(ROR1 + ) and HT-29(ROR1 + ) cells, but not PAN02(ROR1 - ) Cell lysis, such as Fig.10 shown.
[0324] Example 11: Cytotoxicity test
[0325] Method 1
[0326] Cytotoxicity was assessed by LDH release assay using a CytoTox kit. Non-Radioactive Cytotoxicity Assay (Promega, Catalog No.: G1780).
[0327] Anti-ROR1-CAR-T cells or PBMCs were combined with MDA-MB-231 (ROR1 + )、PANC-1(ROR1 + )、NCL-H358(ROR1 + )、NCL-H1975(ROR1 + )、A549(ROR1 + )、HT-29(ROR1 + )、Jeko-1(ROR1 + ) or PAN02(ROR1 - ) cells were co-cultured for 4-6 hours. The details of the cytotoxicity assay are as follows: First, target cells (ROR1 + ) and non-target cells (ROR1 - ) and washed twice with washing buffer, and the cells were suspended in RPMI1640 containing 2% FBS and diluted to 1×10 5 The anti-ROR1-CAR-T cells and PBMC cells (effector cells) were then recovered and diluted to 2×10 6 cells / mL, 1×10 6 cells / mL, 0.5×10 6 cells / mL, 1×10 5The above cells were added to a 96-well plate (200 μL) at a concentration of cells / mL. The composition of each group is shown in Table 5. The ratio of effector cells: target cells was 20:1, 10:1, 5:1, and 1:1, respectively. Then, the cells were cultured at 37°C for 4-6 hours. 20 μL of 10× lysis solution (from the detection kit) was added to the maximum target cell release group 45 minutes before the end of the experiment; 50 μL of supernatant was taken out of each well and transferred to a new 96-well plate, and then 50 μL of substrate was added to the 96-well plate and incubated at room temperature in the dark for 30 minutes; finally, 50 μL of stop solution was added and the absorbance was measured at a wavelength of 490 nm. The percentage of specific lysis was calculated using the following formula:
[0328] (X–Effector–Target Auto Release+background value) / (YB)
[0329] Table 5. Experimental group design of LDH release test
[0330]
[0331] Method 2
[0332] Cytotoxicity was assessed by LDH release assay using a CytoTox kit. Non-Radioactive Cytotoxicity Assay (Promega, Catalog No.: G1780).
[0333] Anti-ROR1-CAR-T cells or PBMCs were co-cultured with ROR1-overexpressing SK-OV-3 and U87MG cells (ROR1 + ) or SK-OV-3 and U87MG cells (ROR1 - ) for 4-6 hours. The specific steps of the cytotoxicity test are as follows: First, recover the target cells (ROR1 + ) and non-target cells (ROR1 - ) and washed twice with washing buffer, and the cells were suspended in RPMI1640 containing 2% FBS and diluted to 1×10 5 The anti-ROR1-CAR-T cells and PBMC cells (effector cells) were then recovered and diluted to 2×10 6 cells / mL, 1×10 6 cells / mL, 0.5×10 6 cells / mL, 1×10 5The above cells were added to a 96-well plate (200 μL) at a concentration of cells / mL. The composition of each group is shown in Table 6. The ratio of effector cells: target cells was 20:1, 10:1, 5:1, and 1:1, respectively. Then, they were cultured at 37°C for 4-6 hours. 20 μL of 10× lysis solution (from the detection kit) was added to the maximum target cell release group 45 minutes before the end of the experiment; 50 μL of supernatant was taken out of each well and transferred to a new 96-well plate, and then 50 μL of substrate was added to the 96-well plate and incubated at room temperature in the dark for 30 minutes; finally, 50 μL of stop solution was added and the absorbance was measured at a wavelength of 490 nm. The percentage of specific lysis was calculated using the following formula:
[0334] (X–Effector–Target Auto Release+background value) / (YB)
[0335] Table 6. Experimental group design of LDH release test
[0336]
[0337] Various modifications to the embodiments are obvious to those skilled in the art. The steps defined in Method 1 and Method 2 are universal and can be used for the analysis of other anti-ROR1-CAR-T cells.
[0338] 11.1 Analysis of anti-ROR1-C3-CAR-T cells
[0339] Method 1 was used to evaluate the cytotoxicity of anti-ROR1-C3-CAR-T cells. Fig.11 As shown, anti-ROR1-C3-CAR-T cells have obvious cytotoxicity against ROR1-positive tumor cells, but not against ROR1-negative tumor cells, proving that CAR-T cells have the ability to specifically kill ROR1-positive tumor cell lines and have no killing effect on normal cells.
[0340] 11.2 Analysis of anti-ROR1-G3-CAR-T cells
[0341] Method 2 was used to evaluate the cytotoxicity of anti-ROR1-G3-CAR-T cells. Fig.12 As shown, anti-ROR1-G3-CAR-T cells had obvious cytotoxicity against ROR1-overexpressing SK-OV-3 and U87MG cells, but had no cytotoxicity against SK-OV-3 and U87MG cells, demonstrating that CAR-T cells have the ability to specifically kill ROR1-positive tumor cell lines and have no killing effect on normal cells.
[0342] Example 12: Safety test of anti-ROR1-CAR-T cells
[0343] To evaluate the safety of anti-ROR1-CAR-T cells, 8-week-old NSG mice (purchased from Shanghai Model Organism Center) were used in this example. The mice were housed in a facility with a temperature of 20-25°C and a relative humidity of 40-70% and inoculated subcutaneously with 5×10 6 One week later, when the tumor volume of mice reached 100 mm 3 They were injected with different doses of anti-ROR1-CAR-T cells, control T cells or PBS solution.
[0344] A total of 40 tumor-bearing mice were divided into 5 groups, each with 4 male mice and 4 female mice; the first group was given 1×10 6 CAR-T cells, and the second group was given 5×10 6 CAR-T cells, and the third group was given 1×10 7 CAR-T cells, and the fourth group was given 1×10 7 Normal T cells were injected into the fifth group, and PBS solution was injected as a control. After the mice were injected with CAR-T cells, the adverse reactions and activity status of the mice were closely observed every day for a total of 28 days. The body weight was recorded from the day of injection of CAR-T cells and recorded every week until the 28th day. After the study, the mice were euthanized and the bodies were dissected to observe the pathological changes of the main organs. No pathological changes were found in the heart, liver, spleen, lung, kidney, stomach, intestine, brain, cerebellum, and lymph nodes, and no abnormal symptoms were found in the respiratory system, digestive system, and cranial nervous system. Therefore, anti-ROR1-CAR-T cells showed high safety in NSG tumor-bearing mice.
[0345] Various modifications to the examples will be apparent to those skilled in the art, and the methods defined herein may be used to analyze any anti-ROR1-CAR-T cells.
[0346] Example 13: Anti-ROR1-CAR-T cell function detection
[0347] Method 1
[0348] To evaluate the in vivo functionality of the anti-ROR1-scFV sequences of each CAR, a mouse tumor-bearing model was used in which MB-MDA-231 tumor cells expressing firefly luciferase were transduced. 7 cells were injected subcutaneously into NOD-Prkdc scid Iq em1 / Smoc mice (purchased from Shanghai Model Organism Center), and then 1×10 7 Anti-ROR1-CAR-T cells were injected into the tumor, and MDA-MB-231 cells were inoculated in NSG mice. After 44 days, anti-ROR1-CAR-T cells were injected and tumor size was measured.
[0349] Method 2
[0350] To evaluate the in vivo functionality of the anti-ROR1-scFV sequences of each CAR, mouse tumor models were used that transduced ROR1-overexpressing Jeko-1, SK-OV-3, and U87MG cells expressing firefly luciferase. 6 Jeko-1 cells were injected into NOD-Prkdc cells by tail vein scid Iq em1 / Smoc mice (purchased from Shanghai Model Organism Center) were then intravenously injected with different doses of anti-ROR1-CAR-T cells on day 2 or day 12; in the ovarian cancer xenograft model, 1×10 6 SK-OV-3-ROR1 cells were injected intraperitoneally into NOD-Prkdc scid Iq em1 / Smoc mice were then injected intraperitoneally with 1×10 7 In the brain glioma xenograft model, 1×10 5 U87MG-ROR1 cells were injected intracranially into NOD-Prkdc scid Iq em1 / Smoc mice, and then on day 5, 2×10 6 Anti-ROR1-CAR-T cells were injected into the tumor and tumor size was measured.
[0351] Various modifications to the embodiments are obvious to those skilled in the art. The steps defined in Method 1 and Method 2 are universal and can be used for the analysis of other anti-ROR1-CAR-T cells.
[0352] 13.1 Analysis of anti-ROR1-C3-CAR-T cells
[0353] Method 1 was used to evaluate the function of anti-ROR1-C3-CAR-T cells. The results are as follows Fig.13 According to the tumor growth curve, the tumor growth of mice injected with anti-ROR1-C3-CAR-T cells was significantly inhibited, while the tumor growth of the PBMC group was normal.
[0354] 13.2 Analysis of anti-ROR1-G3-CAR-T cells
[0355] Method 2 was used to evaluate the function of anti-ROR1-G3-CAR-T cells, and the results are shown in Fig.14 , Fig.15 , Fig.16 and Fig.17 .
[0356] In multiple animal models, anti-ROR1-G3-CAR-T cell therapy can prevent tumor progression. According to the tumor growth curve, the tumor growth of mice injected with anti-ROR1-G3-CAR-T cells was significantly inhibited, while the tumor growth of the PBMC group was normal.
[0357] Example 14: Isolation and enrichment of double negative T cells from healthy human peripheral blood
[0358] 14.1 Isolation of DNT cells from peripheral blood
[0359] Collect 20-50 mL of peripheral blood using two disposable vacuum tubes containing sodium citrate and use RosetteSep TM HumanCD8 Depletion Kit (Stemcell, Cat. No. 15663) and RosetteSep TM Human CD4 Depletion Kit (Stemcell, Catalog No.: 15662) was used to separate DNT cells. The separation process is briefly described as follows: First, 50 μL / mL of anti-human CD4 and CD8 depletion cocktail (Depletion Cocktail) was added to the freshly collected blood sample and incubated at room temperature for 20 minutes, then an equal volume of physiological saline was added to the blood sample; then, the blood sample was added to 50 mL of SepMate containing 15 mL of density gradient centrifugation ficoll-paque-plus (GE, Catalog No.: 17-1440-02) TM -50 tubes (Stemcell, Cat. No. 104950), SepMate TM -50 tubes were centrifuged at 1200 g for 15 minutes to collect PBMCs without CD4 and CD8 positive T cells at the interface of polysucrose and plasma; finally, the recovered PBMCs were centrifuged at 150 g for 10 minutes with 0.87% saline and washed three times.
[0360] 14.2 Enrichment of DNT cells from peripheral blood
[0361] Human Pan T Cell isolation Kit (Miltenyi, Cat. No. 130-096-535) was used to enrich DNT cells from PBMCs obtained in 14.1 without CD4 and CD8 positive T cells. The enrichment steps were as follows: First, PBMCs were isolated at 1×10 7 / 40μL density was washed and suspended in pre-cooled PBS, then 10μL / 1×10 7The cells were incubated with Pan T Cell Biotin-Antibody cocktail at 4°C for 5 minutes, and then 30 μL PBS and 20 μL Pan T Cell Microbead cocktail were added and incubated at 4°C for 10 minutes; the above cells were added to the LS column (Miltenyi, Cat. No.: 130-042-401) and separated by magnetic stand; finally, the obtained DNT cells were washed 3 times with PBS. Flow cytometry was used to detect CD3 + (BD, item number: 552852), CD4 - (BD, Part No. 555347) and CD8 - (BD, Catalog No.: 555369) The proportion of cell subpopulations, the results are as follows Fig.19 shown.
[0362] After separation and enrichment, about 35% of the cells are DNT cells, which have a high purity and can be used to resist ROR1-G3-CAR lentiviral infection.
[0363] Example 15: Anti-ROR1-G3-CAR lentivirus infection of DNT cells
[0364] DNT cells were cultured at 1.5 × 10 6 / mL and seeded in 6-well plates, each well containing 2mL of culture medium, cells were activated with 5μg / mL CD3 (Miltenyi, Catalog No.: 170-076-116) and 0.5μg / mL CD28 (Miltenyi, Catalog No.: 170-076-116) soluble antibodies and 15μg / mL Retronectin (Takara, Catalog No.: T100A), and the next day, anti-ROR1-G3-CAR lentivirus with an MOI of 5 and 15 was added to each well. Two days later, cells were recovered and cultured at 1.5×10 6 / mL and used for FACS and co-culture experiments four days later.
[0365] Example 16: Evaluation of the efficiency and phenotype of anti-ROR1-G3-CAR-DNT cells by FACS
[0366] A lentiviral vector was constructed to express anti-ROR1-CAR and green fluorescent protein separated by self-cleaving peptide 2A to examine the expression efficacy of anti-ROR1-G3-CAR. The expression efficiency of anti-ROR1-G3-CAR was confirmed by detecting green fluorescent protein by flow cytometry fluorescence sorting (FACS). The infection efficiency test and phenotypic analysis were as follows: First, 1×10 6The cells were infected with the aforementioned lentivirus, washed twice with washing buffer, and then 15 μL APC anti-human CD8 antibody (BD, Catalog No.: 555369), 15 μL PE anti-human CD4 antibody (BD, Catalog No.: 555347), and 15 μL PerCY5.5 anti-human CD3 antibody (BD, Catalog No.: 552852) were added, and incubated at 4°C in the dark for 30 minutes; the second step was to centrifuge the sample at 1000 rpm at room temperature for 5 minutes, and then remove the supernatant; the third step was to add FACS buffer to rinse twice, and then centrifuge at 1000 rpm at room temperature for 5 minutes; finally, the cells were suspended with 150 μL FACS buffer, and fluorescence was detected by FACS. The results are shown in FIG. Fig. 20 shown.
[0367] The infection efficiency of DNT cells was approximately 43% at an MOI of 5 and 55% at an MOI of 15, and the anti-ROR1-G3-CAR-DNT cells were all CD4- and CD8-negative T cells.
[0368] Example 17: Evaluation of in vitro proliferation of anti-ROR1-G3-CAR-DNT cells
[0369] To confirm the ability of anti-ROR1-G3-CART cell proliferation in vitro, DNT cells were collected on the third day after lentivirus infection and cultured in TexMACS (Miltenyi, Catalog No.: 170-076-309) + 10% FBS + 200IU / mL IL-2 (Miltenyi, Catalog No.: 130-097-748) + 5ng / mL IL-4 (Proptech, Catalog No.: 200-07-10) + 10ng / mL IL-7 (Proptech, Catalog No.: 200-04-5) + 10ng / mL IL-15 (Proptech, Catalog No.: 200-15-10) + 100μg / mL penicillin and 100μg / mL streptomycin for 4 days.
[0370] On day 7, the anti-ROR1-G3-CAR-DNT cells were collected, washed 1-2 times with PBS, and cultured in complete medium containing 100 ng / mL CD3 (Miltenyi, Catalog No.: 170-076-116), and then replaced with complete medium containing 100 ng / mL CD3 (Miltenyi, Catalog No.: 170-076-116) every 3 to 4 days for 21 days. During the culture process, the number of anti-ROR1-G3-CAR-DNT cells was recorded every 3 to 4 days.
[0371] The number of anti-ROR1-G3-CAR-DNT cells was Fig. 22On the 18th day of culture, the anti-ROR1-G3-CAR-DNT cells could be expanded more than 500 times. However, after the 18th day, the number of anti-ROR1-G3-CAR-DNT cells gradually decreased, which may be due to the long in vitro culture time of anti-ROR1-G3-CAR-DNT cells, leading to cell apoptosis.
[0372] Example 18: Cytokine release assay of anti-ROR1-G3-CAR-DNT cells
[0373] The biological activity of anti-ROR1-G3-CAR-DNT cells on ROR1-overexpressing U87MG cells was evaluated by using a human TH1 / TH2 cytokine CBA kit (BD, Cat. No. 550749). Anti-ROR1-G3-CAR-DNT cells or PBMCs were co-cultured with ROR1-overexpressing U87MG cell lines for 24 hours. The specific steps of the experiment were as follows: First, target cells (ROR1-overexpressing U87MG cells) and non-target cells (U87MG) were recovered and washed twice with washing buffer, and the cells were suspended in RPMI1640 containing 2% FBS and diluted to 1×10 6 The anti-ROR1-G3-CAR-DNT cells and PBMC cells (effector cells) were then recovered and diluted to 1×10 6 At a concentration of 1 cell / mL, 100 μL of target cells (ROR1 overexpressing U87MG cells) and non-target cells (U87MG) were mixed with 100 μL of anti-ROR1-G3-CAR-DNT cells or PBMCs at a ratio of 1:1 into a 96-well plate and co-cultured at 37°C for 20-24 hours; second, 100 μL of culture medium was recovered and centrifuged at 1000 rpm for 5 minutes, and the supernatant was used for cytokine release detection; third, the cytokine capture beads were taken out and mixed thoroughly, 50 μL of the mixed beads and 50 μL of PE detection reagent were added to each supernatant sample (50 μL), mixed thoroughly and incubated at room temperature in the dark for 3 hours, then washing buffer was added to each sample and centrifuged at 200 g for 5 minutes, after removing the supernatant, 300 μL of washing buffer was added to each sample to suspend the beads; finally, the samples were analyzed by flow cytometry.
[0374] The results are as follows Fig.13As shown, anti-ROR1-G3-CAR-DNT cells release IL-2, TNFα, and IFNγ only in the presence of target cells (ROR1 overexpressing U87MG cells). This means that anti-ROR1-G3-CAR-DNT cells only produce cytokines when co-cultured with ROR1-positive target cells (ROR1 overexpressing U87MG cells), but not when co-cultured with ROR1-negative cells (U87MG), proving that CAR-T cells have the ability to specifically kill ROR1-positive tumor cell lines, but have no killing effect on normal cells.
[0375] Example 19: Cell lysis ability test of anti-ROR1-G3-CAR-DNT cells
[0376] U87MG and ROR1 overexpressing U87MG cells were cultured at 1×10 5 The cells were seeded at a concentration of 10 cells / well in a 24-well plate, and an equal amount of anti-ROR1-G3-CAR-DNT cells were added to the culture medium without adding exogenous cytokines. After 24 hours of culture, the residual tumor cells and anti-ROR1-G3-CAR-DNT cells were measured by FACS, and the anti-ROR1-G3-CAR-DNT cells were identified by the expression of CD3 and GFP, while the tumor cells were identified by the expression of B7H3.
[0377] The results are as follows Fig.24 As shown, anti-ROR1-G3-CAR-DNT cells exerted significant cytotoxicity against ROR1-overexpressing U87MG cells, but had no cytotoxicity against U87MG cells, demonstrating that CAR-T cells have the ability to specifically kill ROR1-positive tumor cell lines while having no killing effect on normal cells.
[0378] All documents mentioned in the present invention are cited in the present application documents as references with equivalent contents. In addition, it should be understood that those skilled in the art can make various modifications or adjustments to the present invention after reading the contents of the present invention, and these equivalents will also fall within the scope defined by the claims of the present application. Sequence Listing <110> Nanjing AMF Biopharmaceutical Technology Co., Ltd. <120> ROR1-specific chimeric antigen receptor and its therapeutic application <130> P2019-1976 <141> 2022-03-25 <160> 42 <170> SIPOSequenceListing 1.0 <210> 1 <211> 123 <212> PRT <213> Artificial Sequence <400> 1 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Leu Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Met His Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys 50 55 60 Gly Arg Leu Thr Ile Ser Val Asp Thr Ser Thr Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Gly Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Tyr Tyr Tyr His Asp Ser Ser Gly Tyr Tyr Ser Tyr Phe Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2 <211> 5 <212> PRT <213> Artificial Sequence <400> 2 Ser Tyr Tyr Trp Ser 1 5 <210> 3 <211> 16 <212> PRT <213> Artificial Sequence <400> 3 Tyr Met His Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Gly 1 5 10 15 <210> 4 <211> 15 <212> PRT <213> Artificial Sequence <400> 4 Tyr Tyr Tyr His Asp Ser Ser Gly Tyr Tyr Ser Tyr Phe Asp Tyr 1 5 10 15 <210> 5 <211> 107 <212> PRT <213> Artificial Sequence <400> 5 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 6 <211> 11 <212> PRT <213> Artificial Sequence <400> 6 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 7 <211> 7 <212> PRT <213> Artificial Sequence <400> 7 Asp Ala Ser Asn Arg Ala Ser 1 5 <210> 8 <211> 9 <212> PRT <213> Artificial Sequence <400> 8 Gln Gln Arg Ser Asn Trp Pro Pro Thr 1 5 <210> 9 <211> 8 <212> PRT <213> Artificial Sequence <400> 9 Gly Gly Ser Ile Ser Ser Tyr Tyr 1 5 <210> 10 <211> 7 <212> PRT <213> Artificial Sequence <400> 10 Met His Tyr Ser Gly Ser Thr 1 5 <210> 11 <211> 17 <212> PRT <213> Artificial Sequence <400> 11 Ala Arg Tyr Tyr Tyr His Asp Ser Ser Gly Tyr Tyr Ser Tyr Phe Asp 1 5 10 15 Tyr <210> 12 <211> 6 <212> PRT <213> Artificial Sequence <400> 12 Gln Ser Val Ser Ser Tyr 1 5 <210> 13 <211> 39 <212> PRT <213> Artificial Sequence <400> 13 Asp Ala Ser Asn Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser 1 5 10 15 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu 20 25 30 Asp Phe Ala Val Tyr Tyr Cys 35 <210> 14 <211> 9 <212> PRT <213> Artificial Sequence <400> 14 Gln Gln Arg Ser Asn Trp Pro Pro Thr 1 5 <210> 15 <211> 121 <212> PRT <213> Artificial Sequence <400> 15 Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn His Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly His Ser Ser Gly Trp Tyr Arg Arg Tyr Phe Asp Leu Trp Gly 100 105 110 Arg Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 16 <211> 5 <212> PRT <213> Artificial Sequence <400> 16 Gly Tyr Tyr Trp Ser 1 5 <210> 17 <211> 16 <212> PRT <213> Artificial Sequence <400> 17 Glu Ile Asn His Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 18 <211> 13 <212> PRT <213> Artificial Sequence <400> 18 Gly His Ser Ser Gly Trp Tyr Arg Arg Tyr Phe Asp Leu 1 5 10 <210> 19 <211> 107 <212> PRT <213> Artificial Sequence <400> 19 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Lys Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 20 <211> 11 <212> PRT <213> Artificial Sequence <400> 20 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 21 <211> 7 <212> PRT <213> Artificial Sequence <400> 21 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 22 <211> 9 <212> PRT <213> Artificial Sequence <400> 22 Gln Gln Arg Ser Asn Trp Pro Pro Thr 1 5 <210> 23 <211> 8 <212> PRT <213> Artificial Sequence <400> 23 Gly Gly Ser Phe Ser Gly Tyr Tyr 1 5 <210> 24 <211> 7 <212> PRT <213> Artificial Sequence <400> 24 Ile Asn His Ser Gly Ser Thr 1 5 <210> 25 <211> 15 <212> PRT <213> Artificial Sequence <400> 25 Ala Arg Gly His Ser Ser Gly Trp Tyr Arg Arg Tyr Phe Asp Leu 1 5 10 15 <210> 26 <211> 6 <212> PRT <213> Artificial Sequence <400> 26 Gln Ser Val Ser Ser Tyr 1 5 <210> 27 <211> 39 <212> PRT <213> Artificial Sequence <400> 27 Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Lys Phe Ser Gly Ser 1 5 10 15 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu 20 25 30 Asp Phe Ala Val Tyr Tyr Cys 35 <210> 28 <211> 9 <212> PRT <213> Artificial Sequence <400> 28 Gln Gln Arg Ser Asn Trp Pro Pro Thr 1 5 <210> 29 <211> 123 <212> PRT <213> Artificial Sequence <400> 29 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Leu Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Asn Trp Asn Asp Val Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 30 <211> 5 <212> PRT <213> Artificial Sequence <400> 30 Asp Tyr Ala Met His 1 5 <210> 31 <211> 17 <212> PRT <213> Artificial Sequence <400> 31 Leu Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 32 <211> 14 <212> PRT <213> Artificial Sequence <400> 32 Asp Asn Trp Asn Asp Val Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 33 <211> 107 <212> PRT <213> Artificial Sequence <400> 33 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly 1 5 10 15 Asp Thr Val Thr Ile Ser Cys Gln Ala Ser Arg Asp Ile Ser Asp Tyr 20 25 30 Leu Asn Trp Tyr Gln His Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Ala Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Lys Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Phe Cys Gln Gln Asp Asp Leu Leu Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 <210> 34 <211> 11 <212> PRT <213> Artificial Sequence <400> 34 Gln Ala Ser Arg Asp Ile Ser Asp Tyr Leu Asn 1 5 10 <210> 35 <211> 7 <212> PRT <213> Artificial Sequence <400> 35 Asp Ala Ser Asn Leu Ala Thr 1 5 <210> 36 <211> 9 <212> PRT <213> Artificial Sequence <400> 36 Gln Gln Asp Asp Leu Leu Pro Leu Thr 1 5 <210> 37 <211> 8 <212> PRT <213> Artificial Sequence <400> 37 Gly Phe Thr Phe Asp Asp Tyr Ala 1 5 <210> 38 <211> 8 <212> PRT <213> Artificial Sequence <400> 38 Ile Ser Gly Asp Gly Gly Ser Thr 1 5 <210> 39 <211> 16 <212> PRT <213> Artificial Sequence <400> 39 Ala Arg Asp Asn Trp Asn Asp Val Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 40 <211> 6 <212> PRT <213> Artificial Sequence <400> 40 Arg Asp Ile Ser Asp Tyr 1 5 <210> 41 <211> 39 <212> PRT <213> Artificial Sequence <400> 41 Asp Ala Ser Asn Leu Ala Thr Gly Val Pro Ser Arg Phe Ser Gly Ser 1 5 10 15 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Lys Ser Leu Gln Pro Glu 20 25 30 Asp Val Ala Thr Tyr Phe Cys 35 <210> 42 <211> 9 <212> PRT <213> Artificial Sequence <400> 42 Gln Gln Asp Asp Leu Leu Pro Leu Thr 1 5
Claims
1. A chimeric antigen receptor, comprising: (1) an extracellular domain comprising at least one antigen binding domain or scFv that specifically binds to ROR1; (2) Hinge region; (3) transmembrane region; (4) Intracellular signaling domain; wherein the antigen binding domain or scFv comprises a heavy chain variable region having HCDR1, HCDR2 and HCDR3, and a light chain variable region having LCDR1, LCDR2 and LCDR3; Wherein, the polypeptide sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are selected from: SEQ ID NOs: 16, 17, 18, 20, 21, 22, and the corresponding encoding rules are Kobat encoding rules; or, The polypeptide sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are selected from: amino acids 1-2 (DA), 28 of SEQ ID NOs: 23, 24, 25, 26, 27, and the corresponding coding rules are IMGT coding rules.
2. The chimeric antigen receptor of claim 1, wherein the antigen binding domain comprises: The heavy chain variable region has the polypeptide sequence of SEQ ID NO:15 and the light chain variable region has the polypeptide sequence of SEQ ID NO:
19.
3. The chimeric antigen receptor of claim 1, wherein the scFv is represented by formula A or formula B: V H -V L (A); V L -V H (B); in, V H V is the variable region of the antibody heavy chain, L is an antibody light chain variable region, "-" is a connecting peptide or peptide bond, and the scFv has a heavy chain variable region with a polypeptide sequence of SEQ ID NO: 15 and a light chain variable region with a polypeptide sequence of SEQ ID NO:
19.
4. The chimeric antigen receptor of claim 3, wherein the connecting peptide is (GGGGS)n, wherein n is 1, 2, 3 or 4.
5. The chimeric antigen receptor of claim 1, wherein the structure of the chimeric antigen receptor is as shown in Formula I: L-scFv-H-TM-C-CD3ζ (I) in, L represents no or signal peptide sequence; scFv represents ROR1 antigen-binding domain; H stands for None or Hinge; TM stands for transmembrane domain; C represents the costimulatory signaling domain; CD3ζ represents the intracellular signaling sequence derived from CD3ζ; Each "-" represents an independent connecting peptide or peptide bond.
6. The chimeric antigen receptor of claim 5, wherein L is a signal peptide selected from the group consisting of CD8, CD28, GM-CSF, CD4, CD137, and combinations thereof.
7. The chimeric antigen receptor of claim 5, wherein L is a signal peptide derived from CD8.
8. The chimeric antigen receptor of claim 5, wherein H is a hinge region selected from the group consisting of CD8, CD28, CD137, and combinations thereof.
9. The chimeric antigen receptor of claim 5, wherein H is derived from the hinge region of CD8.
10. The chimeric antigen receptor of claim 5, wherein TM is a transmembrane region selected from CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, and combinations thereof. The chimeric antigen receptor of claim 5 , wherein TM is a transmembrane region derived from CD8 or CD28.
12. The chimeric antigen receptor of claim 5, wherein C is a co-stimulatory signaling domain selected from OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137), PD1, Dap10, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), NKG2D, GITR, TLR2, and combinations thereof.
13. The chimeric antigen receptor of claim 5, wherein C is a co-stimulatory signaling domain derived from CD28 and / or 4-1BB.
14. A nucleic acid molecule encoding the chimeric antigen receptor of any one of claims 1 to 13.
15. A vector comprising the nucleic acid molecule of claim 14.
16. The vector of claim 15, wherein the vector is selected from the group consisting of a plasmid, a viral vector, and a combination thereof.
17. An engineered host cell comprising the vector of claim 15, or the nucleic acid molecule of claim 14 integrated into the chromosome or genome, or expressing the chimeric antigen receptor of any one of claims 1-13.
18. An engineered immune cell comprising the vector of claim 15, or the nucleic acid molecule of claim 14 integrated into a chromosome or genome, or expressing the chimeric antigen receptor of any one of claims 1 to 13.
19. The engineered immune cell of claim 18, which is an autologous or allogeneic cell.
20. The engineered immune cell of claim 18, wherein the engineered immune cell is selected from: Chimeric antigen receptor T cells.
21. The engineered immune cell of claim 20, wherein the T cell is a cytotoxic T cell.
22. The engineered immune cell of claim 20, wherein the T cell is a double negative T cell.
23. The engineered immune cell of claims 18-22, wherein the engineered immune cell expresses a ROR1-specific chimeric antigen receptor on the cell surface.
24. A pharmaceutical composition comprising: (1) the chimeric antigen receptor of any one of claims 1-13, the vector of claim 15 or the engineered immune cell of any one of claims 18-23, and (2) a pharmaceutically acceptable carrier, diluent or excipient.
25. The pharmaceutical composition according to claim 24, which is a liquid preparation.
26. The pharmaceutical composition according to claim 24, which is an injection.
27. The pharmaceutical composition according to claim 24, wherein the concentration of engineered immune cells in the pharmaceutical composition is 1×10 3 -1×10 8 cells / mL.
28. Use of the chimeric antigen receptor of any one of claims 1-13 or the engineered immune cell of any one of claims 18-23 in the preparation of a drug or preparation for treating cancer, wherein the cancer is one or more of breast cancer, non-small cell lung cancer, lung adenocarcinoma, colorectal adenocarcinoma and mantle cell lymphoma.
29. A method for preparing an engineered immune cell, wherein the engineered immune cell expresses the chimeric antigen receptor of any one of claims 1 to 13, wherein: The method comprises the following steps: transducing the nucleic acid molecule of claim 14 or the vector of claim 15 into immune cells, thereby obtaining engineered immune cells.
30. The method of claim 29, wherein the immune cell is a T cell.
31. The method of claim 30, wherein the T cells are DN T cells.
32. A kit for preparing the engineered immune cell of any one of claims 18-23, the kit comprising a container containing the nucleic acid molecule of claim 14 or the vector of claim 15.
